UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
|
For the quarterly period ended August 29, 2020 |
|
|
|
OR |
|
|
|
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
|
For the transition period from to |
Commission File Number: 1-5742
RITE AID CORPORATION
(Exact name of registrant as specified in its charter)
|
Delaware
|
23-1614034
|
|
|
|
|
30 Hunter Lane,
|
17011
|
Registrant’s telephone number, including area code: (717) 761-2633.
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report):
Not Applicable
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, $1.00 par value |
|
RAD |
|
New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ⌧ No ◻
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “Large Accelerated Filer,” “Accelerated Filer,” “Smaller Reporting Company” and “Emerging Growth Company” in Rule 12b-2 of the Exchange Act.
|
Large Accelerated Filer ◻ |
Accelerated Filer ⌧ |
Non-Accelerated Filer ◻ |
Smaller reporting company ☐ Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange act). Yes ☐ No ⌧
The registrant had 55,224,101 shares of its $1.00 par value common stock outstanding as of September 22, 2020.
RITE AID CORPORATION
TABLE OF CONTENTS
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
Condensed Consolidated Balance Sheets as of August 29, 2020 and February 29, 2020 |
5 |
|
|
6 |
|
|
|
7 |
|
|
|
8 |
|
|
|
9 |
|
|
|
10 |
|
|
|
11 |
|
|
|
12 |
|
|
|
13 |
|
|
Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations |
41 |
|
|
57 |
||
|
58 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
59 |
||
|
59 |
||
|
59 |
||
|
59 |
||
|
59 |
||
|
59 |
||
|
59 |
2
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will” and similar expressions and include references to assumptions and relate to our future prospects, developments and business strategies.
Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:
| ● | the impact of widespread health developments, including the continued impact of the global coronavirus (“COVID-19”) pandemic, and the responses thereto (such as quarantines, shut downs and other restrictions on travel and commercial, social and other activities), including the reinstitution of more stringent regulations, which could materially and adversely affect, among other things, the economic and financial markets and labor resources of the locations in which we operate, access to credit, our front-end and pharmaceutical operations, supply chain, associates and executive and administrative personnel. These widespread health developments, or an increase in the number of cases, could also materially and adversely affect our third-party service providers, including suppliers, vendors and business partners, and customers. The COVID-19 pandemic has resulted in recessionary economic conditions which could negatively impact our sales. Any of these developments could result in a material adverse effect on our business, financial conditions and results of operations; |
| ● | our ability to successfully implement our new business strategy (including any delays or adjustments as a result of COVID-19) and improve the operating performance of our stores; |
| ● | our high level of indebtedness and our ability to satisfy our obligations and the other covenants contained in our debt agreements; |
| ● | general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions, civil unrest (including any resulting store closures, damage, or loss of inventory), as well as other factors specific to the markets in which we operate; |
| ● | the impact of private and public third party payors’ continued reduction in prescription drug reimbursement rates and efforts to encourage mail order; |
| ● | our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs; |
| ● | the risk that changes in federal or state laws or regulations, including the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection and the Affordable Care Act (or "ACA") and any regulations enacted thereunder may occur; |
| ● | the impact of the loss of one or more major third party payor contracts and the risk that providers and state contract changes may occur; |
| ● | the risk that we may need to take further impairment charges if our future results do not meet our expectations; |
| ● | our ability to refinance our indebtedness on terms favorable to us; |
| ● | our ability to sell our calendar 2020 Centers of Medicare and Medicaid Services (“CMS”) receivable, in whole or in part, which could negatively impact our leverage ratio if we do not consummate a sale; |
| ● | our ability to grow prescription count and realize front-end sales growth; |
3
| ● | our ability to achieve cost savings and the other benefits of our organizational restructuring within our anticipated timeframe, if at all; |
| ● | decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in further charges; |
| ● | our ability to manage expenses and our investments in working capital; |
| ● | the continued impact of gross margin pressure in the pharmacy benefit management (“PBM”) industries due to continued consolidation and client demand for lower prices while providing enhanced service offerings; |
| ● | risks related to compromises of our information or payment systems or unauthorized access to confidential or personal information of our associates or customers; |
| ● | our ability to maintain our current pharmacy services business and obtain new pharmacy services business, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration, early price renegotiations prior to contract expirations and the risk that we cannot meet client guarantees; |
| ● | our ability to maintain our current Medicare Part D business and obtain new Medicare Part D business, as a result of the annual Medicare Part D competitive bidding process and meet the financial obligations of our bid; |
| ● | the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments; |
| ● | changes in future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies; |
| ● | the risk that we could experience deterioration in our current Star rating with the CMS or incur CMS penalties and/or sanctions; |
| ● | the nature, cost and outcome of pending and future litigation and other legal or regulatory proceedings, and governmental investigations; |
| ● | other risks and uncertainties described from time to time in our filings with the Securities and Exchange Commission (the “SEC”). |
We undertake no obligation to update or revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise, after the date of this report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations” included herein and in our Annual Report on Form 10-K for the fiscal year ended February 29, 2020, which we filed with the SEC on April 27, 2020 (the “Fiscal 2020 10-K") and our Quarterly Report on Form 10-Q for the thirteen weeks ended May 30, 2020, which we filed on July 2, 2020 (the “First Quarter Fiscal 2021 10-Q”), as well as in “Part I – Item 1A. Risk Factors” of the Fiscal 2020 10-K and in “Part II – Item 1A. Risk Factors” in the First Quarter Fiscal 2021 10-Q. To the extent that COVID-19 adversely affects our business and financial results, it may also have the effect of heightening many of the risk factors described herein, in our Fiscal 2020 10-K and in our First Quarter Fiscal 2021 10-Q.
4
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
(unaudited)
See accompanying notes to condensed consolidated financial statements.
5
RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)
See accompanying notes to condensed consolidated financial statements.
6
RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)
(unaudited)
See accompanying notes to condensed consolidated financial statements.
7
RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)
See accompanying notes to condensed consolidated financial statements.
8
RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)
(unaudited)
See accompanying notes to condensed consolidated financial statements.
9
RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except per share amounts)
(unaudited)
See accompanying notes to condensed consolidated financial statements.
10
RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except per share amounts)
(unaudited)
See accompanying notes to condensed consolidated financial statements.
11
RITE AID CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
See accompanying notes to condensed consolidated financial statements.
12
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
1. Basis of Presentation and Significant Accounting Policies
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are of a recurring nature and, in the opinion of management, are necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen and twenty-six week periods ended August 29, 2020 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Rite Aid Corporation (“Rite Aid”) and Subsidiaries (together with Rite Aid, the “Company”) Fiscal 2020 10-K.
Revenue Recognition
The following table disaggregates the Company’s revenue by major source in each segment for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019:
The Retail Pharmacy segment offers a chain-wide loyalty card program titled wellness+. Individual customers are able to become members of the wellness+ program. Members participating in the wellness+ loyalty card program earn points on a calendar year basis for eligible front-end merchandise purchases and qualifying prescription purchases.
Effective January 1, 2020, members reach specific wellness+ tiers based on points accumulated during the six calendar month periods between January 1st and June 30th, and July 1st through December 31st, which entitles such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 500 points during the six calendar month period between January 1st and June 30th achieves the “Gold” tier, enabling him or her to receive a 20% discount on qualifying purchases of front-end merchandise for the remaining portion of that six calendar month period and for the following six calendar months. There is also a similar “Silver” level with a lower threshold and benefit level. Prior to January 1, 2020, the wellness+ tiers were based on points accumulated for a full calendar year, and entitled such customers to wellness+ benefits for the remainder of that calendar year and also the next calendar year.
13
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
Points earned pursuant to the wellness+ program represent a performance obligation and the Company allocates revenue between the merchandise purchased and the wellness+ points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness+ points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As members receive discounted front-end merchandise or when the benefit period expires, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. For the thirteen week period ended August 29, 2020, the Company recognized $17,286 of deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $23,803 as of August 29, 2020, which is included in other current liabilities. The Retail Pharmacy segment had accrued contract liabilities of $52,668 as of February 29, 2020, which is included in other current liabilities.
The existing wellness+ program will be terminated on December 31, 2020. Members that had earned a discount through June 30, 2020 will be eligible to receive that discount on purchases made through December, 31 2020.
Selling, General and Administrative Expenses
During the thirteen week period ended August 29, 2020, the Company changed its compensated absence policy for certain associates. Under the revised policy, benefits are earned and used within the same year, whereas previously benefits earned in one year could be used within a succeeding year. The impact of this change resulted in a reduction in our associate paid time off “PTO” accrual of approximately $39,800 during the thirteen week period ended August 29, 2020.
Recently Adopted Accounting Pronouncements
In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40), which is intended to provide entities with additional guidance to determine which software implementation costs to capitalize and which costs to expense. The ASU will allow entities to capitalize costs for implementation activities during the application development stage. ASU No. 2018-15 is effective for fiscal years and interim periods within those years beginning after December 15, 2019 (fiscal 2021). Early adoption of ASU 2018-15 is permitted. The adoption of this ASU did not have a material impact on the Company’s financial position, results of operations and cash flows.
In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments, which adds to U.S. GAAP an impairment model (known as the current expected credit loss ("CECL") model), that is based on expected losses rather than incurred losses. Under ASU 2016-13, an entity will recognize, as an allowance, its estimate of lifetime expected credit losses, which the FASB believes will result in more timely recognition of such losses. ASU 2016-13 impacts non-banks as most non-banks have financial instruments or other assets (e.g., trade, contract and lease receivables, financial guarantees, loans and loan commitments and held-to-maturity debt securities). The adoption of this ASU did not have a material impact on the Company’s financial position, results of operations and cash flows.
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 related to the approach for intraperiod tax allocation, the recognition of deferred tax liabilities and the methodology
14
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
for calculating income taxes in the interim period. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU is effective for fiscal years ending after December 15, 2020. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s financial position.
In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement benefits (Topic 715-20). This ASU amends ASC 715 to add, remove and clarify disclosure requirements related to defined benefit pension and other postretirement plans. The ASU eliminates the requirement to disclose the amounts in accumulated other comprehensive income expected to be recognized as part of net periodic benefit cost over the next year. The ASU also removes the disclosure requirements for the effects of a one-percentage-point change on the assumed health care costs and the effect of this change in rates on service cost, interest cost and the benefit obligation for postretirement health care benefits. This ASU is effective for fiscal years ending after December 15, 2020 and must be applied on a retrospective basis. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company’s financial position.
2. Restructuring
Beginning in fiscal 2019, the Company initiated a series of restructuring plans designed to reorganize its executive management team, reduce managerial layers, and consolidate roles. In March 2020, the Company announced the details of its RxEvolution strategy, which includes building tools to work with regional health plans to improve patient health outcomes, rationalizing SKU’s in its front-end offering to free up working capital and update its merchandise assortment, assessing its pricing and promotional strategy, rebranding its retail pharmacy and pharmacy services business, launching its Store of the Future format and further reducing SG&A and headcount, including integrating certain back office functions in the Pharmacy Services segment both within the segment and across Rite Aid.
For the thirteen week period ended August 29, 2020, the Company incurred total restructuring-related costs of $23,186, which are included as a component of SG&A. These costs are as follows:
15
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
For the thirteen week period ended August 31, 2019, the Company incurred total restructuring-related costs of $25,145, which are included as a component of SG&A. These costs are as follows:
For the twenty-six week period ended August 29, 2020, the Company incurred total restructuring-related costs of $58,921, of which $33,158 is included as a component of SG&A and $25,763 is included as a component of cost of revenues. These costs are as follows:
In addition, during the thirteen week period ended May 30, 2020, the Company incurred intangible asset impairment charges of $29,852 in connection with its rebranding initiatives as described in Note 10, Goodwill and Other Intangible Assets.
16
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
For the twenty-six week period ended August 31, 2019, the Company incurred total restructuring-related costs of $68,495, which are included as a component of SG&A. These costs are as follows:
A summary of activity for the twenty-six week period ended August 29, 2020 in the restructuring-related liabilities associated with the programs noted above, which is included in accrued salaries, wages and other current liabilities, is as follows:
| (a) | – Severance and related costs reflect severance accruals, executive search fees, outplacement services and other similar charges associated with ongoing reorganization efforts. |
| (b) | – As part of its March 2019 reorganization, the Company incurred costs with the implementation of a retention plan for certain of its key associates. |
| (c) | – Professional and other fees include costs incurred in connection with the identification and implementation of initiatives associated with restructuring activities. |
| (d) | – Inventory reserve on product lines the Company is exiting and will no longer carry as part of its rebranding initiative. |
The Company anticipates incurring approximately $75,000 during fiscal 2021 in connection with its continued restructuring activities.
17
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
3. Asset Sale to WBA
On September 18, 2017, the Company entered into the Amended and Restated Asset Purchase Agreement with Walgreens Boots Alliance, Inc. (“WBA”) and Walgreen Co., an Illinois corporation and 100% owned subsidiary of WBA (“Buyer”), which amended and restated in its entirety the previously disclosed Asset Purchase Agreement, dated as of June 28, 2017, by and among the Company, WBA and Buyer (the “Original Asset Purchase Agreement”). Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer purchased from the Company 1,932 stores (the “Acquired Stores”), three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of $4,375,000, on a cash-free, debt-free basis (the “Asset Sale” or “Sale”). The Company completed the store transfer process in March of 2018, which resulted in the transfer of all 1,932 stores and related assets to WBA, and received cash proceeds of $4,156,686.
During fiscal 2019, the Company completed the sale of one of its distribution centers and related assets to WBA for proceeds of $61,251. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $14,151, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended March 2, 2019. During fiscal 2020, the Company completed the sale of the second distribution center and related assets to WBA for proceeds of $62,774. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $19,268, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended February 29, 2020. During the first quarter of fiscal 2021, the Company completed the sale of the final distribution center and related assets to WBA for proceeds of $94,289. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $12,690, which was included in the results of operations and cash flows of discontinued operations during the thirteen week period ended May 30, 2020. The transfer of the final distribution center and related assets constitutes the final closing under the Amended and Restated Asset Purchase Agreement.
The Company had agreed to provide transition services to Buyer for up to three years after the initial closing of the Sale. Under the terms of the Transition Services Agreement (“TSA”), the Company provided various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. The term of the TSA had been extended to October 17, 2020, unless earlier terminated. In connection with these services, the Company purchased the related inventory and incurred cash payments for the selling, general and administrative activities, which, the Company billed on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen and twenty-six week periods ended August 29, 2020 were $4,162 and $35,167, respectively, of which $0 is included in Accounts receivable, net. Total billings for these items during the thirteen and twenty-six week periods ended August 31, 2019 were $913,965 and $2,106,756, respectively, of which $196,002 is included in Accounts receivable, net. The Company recorded WBA TSA fees of $388 and $1,467 during the thirteen and twenty-six week periods ended August 29, 2020, respectively, which are reflected as a reduction to selling, general and administrative expenses. The Company recorded WBA TSA fees of $11,308 and $25,533 during the thirteen and twenty-six week periods ended August 31, 2019, respectively, which are reflected as a reduction to selling, general and administrative expenses. In conjunction with the transfer of the final distribution center during the quarter ended May 30, 2020, the Company has substantially completed its obligations under the TSA. On July 14, 2020, the Company entered into a letter agreement with WBA to terminate the services under the TSA, other than certain specified services relating to real estate, accounting, tax, and accounts receivable systems that will continue until no later than October 17, 2020 and certain specified services relating to human resources to be performed after October 17, 2020.
18
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
Based on its magnitude and because the Company exited certain markets, the Sale represented a significant strategic shift that has a material effect on the Company's operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Sale as required by Accounting Standards Codification 210-05-Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the Disposal Group to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended August 29, 2020 and February 29, 2020, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. The Company also revised its discussion and presentation of operating and financial results to be reflective of its continuing operations as required by ASC 205-20.
The carrying amount of the Assets to be Sold, which were included in the Retail Pharmacy segment, have been reclassified from their historical balance sheet presentation to current assets and liabilities held for sale as follows:
The operating results of the discontinued operations that are reflected on the consolidated statements of operations within net income (loss) from discontinued operations are as follows:
| (a) | Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations. |
19
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
The operating results reflected above do not fully represent the Disposal Group’s historical operating results, as the results reported within net income (loss) from discontinued operations only include expenses that are directly attributable to the Disposal Group.
4. Income (Loss) Per Share
Basic income (loss) per share is computed by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company, subject to anti-dilution limitations.
Due to their antidilutive effect, 798 and 1,367 potential common shares related to stock options have been excluded from the computation of diluted income (loss) per share for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019, respectively. Also, excluded from the computation of diluted income (loss) per share for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019 are restricted shares of 1,487 and 1,628, respectively, which are included in shares outstanding.
20
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
5. Lease Termination and Impairment Charges
Lease termination and impairment charges consist of amounts as follows:
Impairment Charges
These amounts include the write-down of long-lived assets at locations that were assessed for impairment because of management’s intention to relocate or close the location or because of changes in circumstances that indicated the carrying value of an asset may not be recoverable.
The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:
| ● | Level 1—Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. |
| ● | Level 2—Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument. |
| ● | Level 3—Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk. |
Non-Financial Assets Measured on a Non-Recurring Basis
Long-lived non-financial assets are measured at fair value on a nonrecurring basis for purposes of calculating impairment using Level 2 and Level 3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level 2 inputs is determined by evaluating the current economic conditions in the geographic area for similar use assets. The fair value of long-lived assets using Level 3 inputs is determined by estimating the amount and timing of net future cash flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest (which is Level 1). The Company estimates future cash flows based on its experience and knowledge of the market in which the store is located. Significant increases or decreases in actual cash flows may result in valuation changes. During the twenty-six week period ended August 29, 2020, long-lived assets from continuing operations with a carrying value of $12,654, were written down to their fair value of $1,221, resulting in an impairment charge of $11,433 of which $9,230 relates to the thirteen week period ended August 29, 2020. Of the $11,433, $4,779 relates to a terminated software
21
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
project and the replacement of existing software, $4,995 relates to the closure of the remaining RediClinic operations and $1,659 relates to store and corporate assets. During the twenty-six week period ended August 31, 2019, long-lived assets from continuing operations with a carrying value of $1,412, primarily store assets, were written down to their fair value of $0, resulting in an impairment charge of $1,412 of which $1,289 relates to the thirteen week period ended August 31, 2019. If our actual future cash flows differ from our projections materially, certain stores that are either not impaired or partially impaired in the current period may be further impaired in future periods.
The following table presents fair values for those assets measured at fair value on a non-recurring basis at August 29, 2020 and August 31, 2019:
The above assets reflected in the caption Long-lived assets held for sale are separate and apart from the Assets to be Sold and due to their immateriality have not been reclassified to assets held for sale.
Lease Termination and Facility Exit Charges
As part of the Company's ongoing business activities, the Company assesses stores and distribution centers for potential closure or relocation. Decisions to close or relocate stores or distribution centers in future periods would result in lease termination charges, lease exit costs and inventory liquidation charges, as well as impairment of assets at these locations. When a store or distribution center is closed, the Company records an expense for unrecoverable costs and accrues a liability equal to the present value at current credit adjusted risk-free interest rates of any anticipated executory costs which are not included within the store or distribution center's respective lease liability under Topic 842. Other store or distribution center closing and liquidation costs are expensed when incurred.
22
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
The following table reflects the closed store and distribution center charges that relate to new closures, changes in assumptions and interest accretion:
6. Fair Value Measurements
The Company utilizes the three-level valuation hierarchy as described in Note 5, Lease Termination and Impairment Charges, for the recognition and disclosure of fair value measurements.
Financial instruments other than long-term indebtedness include cash and cash equivalents, accounts receivable and accounts payable. These instruments are recorded at book value, which we believe approximate their fair values due to their short term nature. In addition, as of August 29, 2020 and February 29, 2020, the Company has $7,020 and $7,022, respectively, of investments carried at amortized cost as these investments are being held to maturity, which are included as a component of other assets. The Company believes the carrying value of these investments approximates their fair value.
The fair value for LIBOR-based borrowings under the Company’s senior secured credit facility is estimated based on the quoted market price of the financial instrument which is considered Level 1 of the fair value hierarchy. The fair values of substantially all of the Company’s other long-term indebtedness are estimated based on quoted market prices of the financial instruments which are considered Level 1 of the fair value hierarchy. The carrying amount and estimated fair value of the Company’s total long-term indebtedness was $3,506,708 and $3,544,160, respectively, as of August 29, 2020. The carrying amount and estimated fair value of the Company's total long-term indebtedness was $3,077,268 and $3,021,385, respectively, as of February 29, 2020.
7. Income Taxes
The Company recorded an income tax expense from continuing operations of $47 and $27,628 for the thirteen week periods ended August 29, 2020 and August 31, 2019, respectively. The Company recorded an income tax benefit from continuing operations of $7,971 and an income tax expense from continuing operations of $35,002 for the twenty-six week periods ended August 29, 2020 and August 31, 2019, respectively. The effective tax rate for the thirteen week periods ended August 29, 2020 and August 31, 2019 was (0.4)% and (54.1)%, respectively. The effective tax rate for the twenty-six week periods ended August 29, 2020 and August 31, 2019 was 8.5% and (24.5)%, respectively. The effective tax rate for the thirteen and twenty-six week periods ended August 29, 2020 was net of an adjustment of 7.6% and
23
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
(8.1)%, respectively, to adjust the valuation allowance against deferred tax assets. The effective tax rate for the thirteen and twenty-six week periods ended August 31, 2019 was net of an adjustment of (78.4)% and (50.2)%, respectively, to increase the valuation allowance against deferred tax assets.
The Company recognizes tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.
The Company believes that it is reasonably possible that a decrease of up to $13,210 in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.
The Company regularly evaluates valuation allowances established for deferred tax assets for which future realization is uncertain. Management will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. The Company continues to maintain a valuation allowance against net deferred tax assets of $1,680,103 and $1,673,119, which relates to federal and state deferred tax assets that may not be realized based on the Company's future projections of taxable income at August 29, 2020 and February 29, 2020, respectively.
8. Medicare Part D
The Company offers Medicare Part D benefits through EIC, which has contracted with CMS to be a PDP and, pursuant to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, must be a risk-bearing entity regulated under state insurance laws or similar statutes.
EIC is a licensed domestic insurance company under the applicable laws and regulations. Pursuant to these laws and regulations, EIC must file quarterly and annual reports with the National Association of Insurance Commissioners (“NAIC”) and certain state regulators, must maintain certain minimum amounts of capital and surplus under formulas established by certain states and must, in certain circumstances, request and receive the approval of certain state regulators before making dividend payments or other capital distributions to the Company. The Company does not believe these limitations on dividends and distributions materially impact its financial position. EIC is subject to minimum capital and surplus requirements in certain states. The minimum amount of capital and surplus required to satisfy regulatory requirements in these states is $16,622 as of June 30, 2020. EIC was in excess of the minimum required amounts in these states as of August 29, 2020.
The Company has recorded estimates of various assets and liabilities arising from its participation in the Medicare Part D program based on information in its claims management and enrollment systems. Significant estimates arising from its participation in this program include: (i) estimates of low-income cost subsidies, reinsurance amounts, and coverage gap discount amounts ultimately payable to CMS based on a detailed claims reconciliation that will occur in the following year; (ii) an estimate of amounts receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor and (iii) estimates for claims that have been reported and are in the process of being paid or contested and for our estimate of claims that have been incurred but have not yet been reported.
24
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
On February 19, 2020, the Company entered into a receivable purchase agreement (the “Receivable Purchase Agreement”) with Bank of America, N.A. (the “Purchaser”).
Pursuant to the terms and conditions set forth in the Receivable Purchase Agreement, the Company sold $501,422 of its calendar 2019 CMS receivable for $484,547, of which $449,949 was received on February 19, 2020. As of August 29, 2020, $30,227, which is included in accounts receivable, net, is payable to the Company, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance from CMS. In connection therewith, the Company recognized a loss of $16,875, which is included as a component of loss on sale of assets, net in the fourth quarter of fiscal 2020.
On February 19, 2020, concurrent with the Receivable Purchase Agreement, the Company entered into an indemnity agreement (the “Indemnity Agreement”), whereby the Company has agreed to indemnify, reimburse and hold Purchaser harmless from certain liabilities and expenses actually suffered or incurred by the Purchaser resulting from the occurrence of certain events as specified in the Indemnity Agreement. Based on its evaluation of the Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the Indemnity Agreement.
As of August 29, 2020, accounts receivable, net included $513,009 due from CMS. As of February 29, 2020, accrued salaries, wages and other current liabilities included $14,083 of amounts due to CMS.
9. Manufacturer Rebates Receivables
The Pharmacy Services Segment has manufacturer rebates receivables of $607,025 and $530,451 included in Accounts receivable, net, as of August 29, 2020 and February 29, 2020, respectively.
10. Goodwill and Other Intangible Assets
There was no goodwill impairment charge for the thirteen and twenty-six week periods ended August 29, 2020. At August 29, 2020 and February 29, 2020, accumulated impairment losses for the Pharmacy Services segment was $574,712.
25
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
The Company’s intangible assets are primarily finite-lived and amortized over their useful lives. Following is a summary of the Company’s finite-lived and indefinite-lived intangible assets as of August 29, 2020 and February 29, 2020.
| (a) | Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows. |
In connection with the RxEvolution initiatives previously announced on March 16, 2020, the Company rebranded its EnvisionRxOptions and MedTrak subsidiaries to its new brand name, Elixir. These trademarks qualify as Level 3 within the fair value hierarchy. Upon the implementation of the rebranding initiatives during the first quarter of fiscal 2021, the Company has determined that the carrying value exceeded the fair value and consequently the Company incurred an impairment charge of $29,852 for these trademarks, which is included within intangible asset impairment charges within the condensed consolidated statement of operations.
Amortization expense for these intangible assets and liabilities was $22,695 and $47,115 for the thirteen and twenty-six week periods ended August 29, 2020, respectively. Amortization expense for these intangible assets and liabilities was $26,596 and $54,256 for the thirteen and twenty-six week periods ended August 31, 2019, respectively. The anticipated annual amortization expense for these intangible assets and liabilities is 2021—$88,157; 2022—$65,889; 2023—$50,659; 2024—$37,003 and 2025—$25,736.
26
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
11. Indebtedness and Credit Agreements
Following is a summary of indebtedness and lease financing obligations at August 29, 2020 and February 29, 2020:
Credit Facility
On December 20, 2018, the Company entered into a senior secured credit agreement (as amended by the First Amendment to Credit Agreement, dated as of January 6, 2020, the “Credit Agreement”), consisting of a $2,700,000 senior secured asset-based revolving credit facility (“Senior Secured Revolving Credit Facility”) and a $450,000 “first-in, last out” senior secured term loan facility (“Senior Secured Term Loan,” and together with the Senior Secured Revolving Credit Facility, collectively, the “Existing Facilities”). The Company used proceeds from the Existing Facilities to refinance its prior $2,700,000 existing credit agreement (the “Old Facility”). The Existing Facilities extend the Company’s debt maturity profile and provide additional liquidity. Borrowings under the Senior Secured Revolving Credit Facility bear interest at a rate per annum between LIBOR plus 1.25% and LIBOR plus 1.75% based upon the
27
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
Average ABL Availability (as defined in the Credit Agreement). Borrowings under the Senior Secured Term Loan bear interest at a rate per annum of LIBOR plus 3.00%. The Company is required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the commitments under the Senior Secured Revolving Credit Facility, depending on Average ABL Availability. The Existing Facilities mature on December 20, 2023, subject to an earlier maturity on December 31, 2022 if the Company has not repaid or refinanced its existing 6.125% Senior Notes due 2023 (the “6.125% Notes”) prior to such date. The Company has refinanced the majority of its 6.125% Notes and intends to refinance or repay the remaining balance prior to the early maturity becoming effective.
The Company’s borrowing capacity under the Senior Secured Revolving Credit Facility is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At August 29, 2020, the Company had $1,750,000 of borrowings outstanding under the Existing Facilities and had letters of credit outstanding against the Senior Secured Revolving Credit Facility of $102,939 which resulted in additional borrowing capacity under the Senior Secured Revolving Credit Facility of $1,297,061. If at any time the total credit exposure outstanding under the Existing Facilities and the principal amount of our other senior obligations exceed the borrowing base, the Company will be required to make certain other mandatory prepayments to eliminate such shortfall.
The Credit Agreement restricts the Company and all of its subsidiaries that guarantee its obligations under the Existing Facilities, the secured guaranteed notes and unsecured guaranteed notes (collectively, the “Subsidiary Guarantors”) from accumulating cash on hand in excess of $200,000 at any time when revolving loans are outstanding (not including cash located in store and lockbox deposit accounts and cash necessary to cover current liabilities). The Credit Agreement also states that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default exists under the Existing Facilities or (ii) the sum of the Company’s borrowing capacity under the Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account is less than $275.0 million for three consecutive business days or less than or equal to $200.0 million on any day (a “cash sweep period”), the funds in the Company’s deposit accounts will be swept to a concentration account with the senior collateral agent and will be applied first to repay outstanding revolving loans under the Existing Facilities, and then held as collateral for the senior obligations until such cash sweep period is rescinded pursuant to the terms of the Existing Facilities.
With the exception of EIC, substantially all of Rite Aid Corporation’s 100% owned subsidiaries guarantee the obligations under the Existing Facilities, the secured guaranteed notes and unsecured guaranteed notes. The Company’s obligations under the Existing Facilities and the Subsidiary Guarantors’ obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivable, inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of their deposit accounts, collectively, the “ABL priority collateral”) and (ii) a second-priority lien on all of the Subsidiary Guarantors’ equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and all other assets that do not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations. The subsidiary guarantees related to the Company’s Existing Facilities, the secured guaranteed notes and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several, and there are no restrictions on the ability of the Company to obtain funds from its subsidiaries. The Company has no independent assets or operations. Other than EIC, the subsidiaries, including joint ventures, that do not guarantee the Existing Facilities and applicable notes, are minor.
28
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
The Credit Agreement allows the Company to have outstanding, at any time, up to an aggregate principal amount of $1,500,000 in secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Existing Facilities and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the Credit Agreement) (excluding bridge facilities allowing extensions on customary terms to at least the date that is 90 days after such date). Subject to the limitations described in clauses (i) and (ii) of the immediately preceding sentence, the Credit Agreement additionally allows the Company to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Credit Agreement) is not in effect; provided, however, that certain of the Company’s other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Credit Agreement also contains certain restrictions on the amount of secured first priority debt the Company is able to incur. The Credit Agreement also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Existing Facilities are not in default and the Company maintains availability under its revolver of more than $365,000.
The Credit Agreement has a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the Senior Secured Revolving Credit Facility is less than $200,000 or (ii) on the third consecutive business day on which availability under the Senior Secured Revolving Credit Facility is less than $250,000 and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $250,000. As of August 29, 2020, the Company’s fixed charge coverage ratio was greater than 1.00 to 1.00, and the Company was in compliance with the Credit Agreement’s financial covenant. The Credit Agreement also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, the making of investments, sale of assets, mergers and acquisitions and the granting of liens.
The Credit Agreement provides for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if the Company fails to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurs that enables, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment, repurchase, redemption or defeasance of such debt.
Fiscal 2020 and 2021 Transactions
On October 11, 2019, the Company completed a privately negotiated purchase from a noteholder and its affiliated funds of $84,097 aggregate principal amount of the 7.70% Notes due 2027 (the “7.70% Notes”) and 6.875% fixed-rate Senior Notes due 2028 (the “6.875% Notes”) for $51,300. In connection therewith, the Company recorded a gain on debt retirement of $32,416, which included unamortized debt issuance costs. The debt repayment and related gain on debt retirement is included in the results of operations and cash flows of continuing operations.
On October 15, 2019, the Company commenced an offer to purchase up to $100,000 of its outstanding 7.70% Notes and its 6.875% Notes. In November 2019, the Company accepted for payment $18,075 aggregate principal amount of the 7.70% Notes and $39,441 aggregate principal amount of the 6.875% Notes for $38,392. In connection therewith, the Company recorded a gain on debt retirement of $18,510, which included unamortized debt issuance costs. The debt
29
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
repayment and related gain on debt retirement is included in the results of operations and cash flows of continuing operations.
During November 2019, the Company made additional purchases of $15,000 aggregate principal amount of the 7.70% Notes for $10,012. In connection therewith, the Company recorded a gain on debt retirement of $4,766, which included unamortized debt issuance costs. The debt repayment and related gain on debt retirement is included in the results of operations and cash flows of continuing operations.
On January 6, 2020, the Company commenced an offer to exchange up to $600,000 aggregate principal amount of the outstanding 6.125% Notes for newly issued 7.500% Senior Secured Notes due 2025 (the “7.500% Notes”). On February 5, 2020, the Company announced that the exchange offer was oversubscribed and accepted for payment $600,000 aggregate principal amount of the 6.125% Notes in exchange for newly issued 7.500% Notes. The Company accounted for the exchange as a debt modification and accordingly did not record a loss on debt retirement.
The 7.500% Notes mature on July 1, 2025, and are guaranteed on a senior secured basis by the same Subsidiary Guarantors that guarantee the Existing Facilities and the 6.125% Notes. The 7.500% Notes and the obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’ equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and other collateral to the extent it does not constitute ABL priority collateral (as defined below), and (ii) a second-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivables, payment intangibles, inventory, prescription files (including eligible script lists) and, intellectual property (prior to the repayment of the Senior Secured Term Loan (collectively, the “ABL priority collateral”), which, in each case, also secure the Existing Facilities.
On June 25, 2020, the Company commenced an offer to exchange (the “June 25, 2020 Exchange Offer”) up to $750,000 aggregate principal amount of the outstanding 6.125% Notes for a combination of $600,000 newly issued 8.0% Senior Secured Notes due 2026 (the “8.0% Notes”) and $145,500 cash. On July 10, 2020, the Company increased the maximum amount of 6.125% Notes that may be accepted for exchange from $750,000 to $1,125,000 and, on July 24, 2020, the Company announced that it accepted for payment $1,062,682 aggregate principal amount of the 6.125% Notes in exchange for $849,918 aggregate principal amount of newly issued 8.0% Notes and $206,373 in cash. In connection therewith, the Company recorded a gain on debt modification of $5,274 which is included in the results of operations and cash flows of continuing operations. The 8.0% Notes are secured on an equal and ratable basis by the same assets that secure the 7.500% Notes. The 8.0% Notes are guaranteed on a senior secured basis by the same subsidiaries that guarantee the 7.500% Notes. In conjunction with the June 25, 2020 Exchange Offer, the Company also commenced a solicitation of consents from the holders of outstanding 6.125% Notes to certain proposed amendments to the indenture governing the 6.125% Notes. On July 9, 2020, following the receipt of the requisite number of consents, the Company entered into a supplemental indenture, by and among the Company, the guarantors thereto and The Bank of New York Mellon Trust Company, N.A., the trustee of the 6.125% Notes, which modified certain limitations in the debt covenant to allow for the creation of the 8.0% Notes.
Maturities
The aggregate annual principal payments of long-term debt for the remainder of fiscal 2021 and thereafter are as follows: 2021—$0; 2022—$0; 2023—$0; 2024—$1,840,808; 2025—$0 and $1,716,305 thereafter. These aggregate
30
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
annual principal payments of long-term debt assume that the Company has repaid or refinanced its existing 6.125% Notes prior to December 31, 2022.
12. Leases
The Company leases most of its retail stores and certain distribution facilities under noncancelable operating and finance leases, most of which have initial lease terms ranging from 5 to 22 years. The Company also leases certain of its equipment and other assets under noncancelable operating leases with initial terms ranging from 3 to 10 years. In addition to minimum rental payments, certain store leases require additional payments based on sales volume, as well as reimbursements for taxes, maintenance and insurance. Most leases contain renewal options, certain of which involve rent increases.
The following table is a summary of the Company’s components of net lease cost for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019:
Supplemental cash flow information related to leases for the twenty-six week periods ended August 29, 2020 and August 31, 2019:
31
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
Supplemental balance sheet information related to leases as of August 29, 2020 and February 29, 2020 (in thousands, except lease term and discount rate):
The following table summarizes the maturity of lease liabilities under finance and operating leases as of August 29, 2020:
| (1) | – Future operating lease payments have not been reduced by minimum sublease rentals of $43 million due in the future under noncancelable leases. |
32
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
During the thirteen and twenty-six week periods ended August 29, 2020, the Company sold one owned operating property, the Company’s Ice Cream Plant, to an independent third party. Net proceeds from the sale were $8,461. Concurrent with this sale, the Company entered into an agreement to lease the property back from the purchaser over a minimum lease term of 15 years. The Company accounted for this lease as an operating lease right-of-use asset and a corresponding operating lease liability in accordance with the Lease Standard. The transaction resulted in a gain of $6,219 which is included in the gain on sale of assets, net for the thirteen week period ended August 29, 2020. During the thirteen and twenty-six week periods ended August 31, 2019, the Company did not enter into any sale-leaseback transactions. The Company has additional capacity under its outstanding debt agreements to enter into additional sale-leaseback transactions.
13. Stock Options and Stock Awards
The Company recognizes share-based compensation expense over the requisite service period of the award, net of an estimate for the impact of forfeitures. Operating results for the twenty-six week periods ended August 29, 2020 and August 31, 2019 include $5,810 and $10,092, respectively, of compensation costs related to the Company’s stock-based compensation arrangements.
The Company provides certain of its associates with performance based incentive plans under which the associates will receive a certain number of shares of the Company’s common stock or cash based on the Company meeting certain financial and performance goals. If such goals are not met, no stock-based compensation expense is recognized and any recognized stock-based compensation expense is reversed. During the twenty-six week periods ended August 29, 2020 and August 31, 2019, the Company incurred expense of $513 compared to a benefit of $348 related to these performance based incentive plans, respectively, which is recorded as a component of stock-based compensation expense.
The total number and type of newly awarded grants and the related weighted average fair value for the twenty-six week periods ended August 29, 2020 and August 31, 2019 are as follows:
Typically, stock options granted vest, and are subsequently exercisable in equal annual installments over a four-year period for employees. Restricted stock awards typically vest in equal annual installments over a three-year period.
The Company calculates the fair value of stock options using the Black-Scholes-Merton option pricing model.
33
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
As of August 29, 2020, the total unrecognized pre-tax compensation costs related to unvested stock options and restricted stock awards granted, net of estimated forfeitures and the weighted average period of cost amortization are as follows:
14. Retirement Plans
Net periodic pension expense for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019, for the Company’s defined benefit plan includes the following components:
During the thirteen and twenty-six week periods ended August 29, 2020 the Company contributed $854 to the Defined Benefit Pension Plan. During the remainder of fiscal 2021, the Company expects to contribute $5,608 to the Defined Benefit Pension Plan.
15. Segment Reporting
The Company has two reportable segments, its retail drug stores (“Retail Pharmacy”), and its pharmacy services (“Pharmacy Services”) segments.
The Retail Pharmacy segment’s primary business is the sale of prescription drugs and related consultation to its customers. Additionally, the Retail Pharmacy segment sells a full selection of health and beauty aids and personal care products, seasonal merchandise and a large private brand product line. The Pharmacy Services segment offers a full range of pharmacy benefit management services including plan design and administration, on both a transparent pass-through model and traditional model, formulary management and claims processing. Additionally, the Pharmacy Services segment offers specialty and mail order services, and drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program.
34
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
The Company’s chief operating decision makers are its Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, and the President—Pharmacy Services, (collectively the “CODM”). The CODM has ultimate responsibility for enterprise decisions. The CODM determines, in particular, resource allocation for, and monitors performance of, the consolidated enterprise, the Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy and Pharmacy Services segment managers have responsibility for operating decisions, allocating resources and assessing performance within their respective segments. The CODM relies on internal management reporting that analyzes enterprise results on certain key performance indicators, namely, revenues, gross profit, and Adjusted EBITDA.
The following is balance sheet information for the Company’s reportable segments:
| (1) | As of August 29, 2020 and February 29, 2020, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $0 against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $15,845 and $14,564, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. |
35
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
The following table is a reconciliation of the Company’s business segments to the consolidated financial statements for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019:
| (1) | Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis. |
| (2) | See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” in MD&A for additional details. |
36
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
The following is a reconciliation of net income (loss) to Adjusted EBITDA for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019:
16. Commitments, Contingencies and Guarantees
Legal Matters and Regulatory Proceedings
The Company is involved in numerous legal matters including litigation, arbitration, and other claims, and is subject to regulatory proceedings including investigations, inspections, audits, inquiries, and similar actions by pharmacy, health care, tax and other governmental authorities arising in the ordinary course of its business, including, without limitation, the matters described below. The Company records accruals for outstanding legal matters and applicable regulatory proceedings when it believes it is probable that a loss has been incurred, and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters and regulatory proceedings that could affect the amount of any existing accrual and developments that would make a loss contingency both probable and reasonably estimable, and as a result, warrant an accrual. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters or regulatory proceedings are material individually or in the aggregate to the Company’s consolidated financial position.
The Company’s contingencies are subject to significant uncertainties, many of which are beyond the Company’s control, including, among other factors: (i) proceedings are in early stages; (ii) whether class or collective
37
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
action status is sought and the likelihood of a class being certified; (iii) the outcome of pending appeals or motions; (iv) the extent of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the matter; (vi) whether novel or unsettled legal theories are at issue or advanced; (vii) there are significant factual issues to be resolved; and/or (viii) in the case of certain government agency investigations, whether a qui tam lawsuit (“whistleblower” action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation. While the Company cannot predict the outcome of any of the contingencies, the Company’s management does not believe that the outcome of any of these legal matters or regulatory proceedings will be material to the Company’s consolidated financial position. It is possible, however, the Company’s results of operations or cash flows could be materially affected by unfavorable outcomes in outstanding legal matters or regulatory proceedings.
California Employment Litigation.
The Company is currently a defendant in several lawsuits filed in courts in California that contain allegations regarding violations of the California Business and Professions Code, various California employment laws and regulations, industry wage orders, wage-and-hour laws, rules and regulations pertaining primarily to failure to pay overtime, failure to pay premiums for missed meals and rest periods, failure to provide accurate wage statements, and failure to reimburse business expenses (the “California Cases”). Some of the California Cases purport or may be determined to be class actions or PAGA representative actions and seek substantial damages and penalties. These single-plaintiff and multi-plaintiff California Cases in the aggregate, seek substantial damages. The Company believes that its defenses and assertions in the California Cases have merit. The Company has aggressively challenged the merits of the lawsuits and, where applicable, allegations that the lawsuits should be certified as class or representative actions. Additionally, at this time the Company is not able to predict either the outcome of or estimate a potential range of loss with respect to the California Cases and is defending itself against these claims.
Usual and Customary and Code 1 Litigation.
In January 2017, qui tam plaintiff Azam Rahimi (“Relator”) filed a sealed False Claims Act (“FCA”) lawsuit in the United States District Court for the Eastern District of Michigan. The United States Attorney’s Office for the Eastern District of Michigan, 18 states, and the District of Columbia declined to intervene. The unsealed lawsuit alleges that the Company failed to report Rite Aid’s Rx Savings Program prices as its usual and customary charges under the Medicare Part D program, federal and state Medicaid programs, and other publicly funded health care programs, and that the Company is thus liable under the federal FCA and similar state statutes. On December 12, 2019, the court granted the Company’s motion to dismiss and judgment on the pleadings based upon the FCA’s public disclosure bar. The Relator filed a motion for reconsideration which was denied. The Relator has appealed from the order granting the Company’s motion to dismiss and for judgment on the pleadings, and also from the order denying his motion for reconsideration. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit and is defending itself against these claims.
The State of Mississippi, by and through its Attorney General, filed a lawsuit against the Company and various purported related entities on September 27, 2016 alleging the Company failed to accurately report usual and customary prices to Mississippi’s Division of Medicaid. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit, and is defending itself against these claims.
38
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
The Company is involved in a putative consumer class action lawsuit in the United States District Court for the Southern District of California captioned Byron Stafford v. Rite Aid Corp. A separate lawsuit, Robert Josten v. Rite Aid Corp., was consolidated with this lawsuit in November, 2019. The lawsuit contains allegations that (i) the Company was obligated to charge the plaintiffs’ insurance companies a “usual and customary” price for their prescription drugs; and (ii) the Company failed to do so because the prices it reported were not equal to or adjusted to account for the prices that Rite Aid offers to uninsured and underinsured customers through its Rx Savings Program. At this stage of the proceedings, the Company is not able to either predict the outcome or estimate a potential range of loss and is defending itself against these claims.
On February 6, 2019, Humana, Inc., filed an arbitration claim alleging that the Company improperly submitted various usual and customary overcharges by failing to report its Rx Savings Program pricing to Humana. At this stage of the proceedings, the Company is not able to either predict the outcome of this arbitration proceeding or estimate a potential range of loss, and is defending itself against these claims.
In June 2012, qui tam plaintiff, Loyd F. Schmuckley (“Relator”) filed a complaint under seal against the Company alleging that it failed to comply with certain requirements of California’s Medicaid program between 2007 and 2014. Specifically, the Relator alleged that the Company did not perform special verification and documentation for certain medications known as “Code 1” drugs. While the complaint remained under seal, the United States Department of Justice conducted an extensive investigation and ultimately declined to intervene. Although numerous states declined to intervene, in September 2017, the State of California filed a complaint in intervention. At this stage of the proceedings, the Company is not able to either predict the outcome of this matter or estimate a potential range of loss with respect to this matter, and is defending itself against these claims.
Controlled Substances Litigation, Audits and Investigations
The Company along with various other defendants are named in multiple opioid-related lawsuits filed by counties, cities, municipalities, Native American tribes, hospitals, third-party payers, and others across the United States. In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated and transferred more than a thousand federal opioid-related lawsuits that name the Company and/or a related entity as a defendant to the multi-district litigation (“MDL”) pending in the United States District Court for the Northern District of Ohio before Judge Dan Polster under In re National Prescription Opiate Litigation (Case No. 17-MD-2804). A significant number of similar cases that are not part of the MDL and name the Company and/or a related entity or entities as a defendant in also are pending in state courts. The plaintiffs in all of these opioid-related lawsuits generally allege claims concerning the impacts of widespread opioid abuse against defendants along the pharmaceutical supply chain, including manufacturers, wholesale distributors, and retail pharmacies. At this stage of the proceedings, the Company is not able to predict the outcome of the opioid-related lawsuits or estimate a potential range of loss regarding the lawsuits. The Company is defending itself against all relevant claims.
The Company also has received warrants, subpoenas, CIDs, and other requests for documents and information from, and is being investigated by, the federal and state governments regarding opioids and other controlled substances. The Company has been cooperating with and responding to these investigatory inquiries.
39
RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the Thirteen and Twenty-Six Week Periods Ended August 29, 2020 and August 31, 2019
(Dollars and share information in thousands, except per share amounts)
(unaudited)
Miscellaneous Litigation and Investigations.
The U.S. Securities and Exchange Commission (“SEC”) is investigating trading in the Company’s securities that occurred in or around January 2017, and has subpoenaed information from the Company in connection with that investigation. The Company is cooperating with the SEC in this matter. In addition to the above described matters, the Company is subject from time to time to various claims and lawsuits and governmental investigations arising in the ordinary course of business. While the Company’s management cannot predict the outcome of any of the claims, the Company’s management does not believe that the outcome of any of these matters will be material to the Company’s consolidated financial position. It is possible, however, that the Company’s results of operations or cash flows could be materially affected by an unfavorable resolution of pending litigation or contingencies.
These other legal proceedings include claims of improper disclosure of personal information, anticompetitive practices, general contractual matters, product liability, professional malpractice, non-compliance with state and federal regulatory regimes, marketing misconduct, intellectual property litigation and employment litigation. Some of these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters.
17. Supplementary Cash Flow Data
| (a) | — Amounts are presented on a total company basis. |
Significant components of cash used in Other Liabilities of $11,484 for the twenty-six week period ended August 29, 2020 include cash used resulting from a decrease in compensation and benefit related accruals of $68,286, partially offset by the employer payroll tax payment deferral under the CARES act of $52,733.
40
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations
Overview
We are a healthcare company with a retail footprint, providing our customers and communities with a high level of care and service through various programs we offer through our two reportable business segments, our Retail Pharmacy segment and our Pharmacy Services segment. We accomplish our goal of delivering comprehensive care to our customers through our retail drugstores and our transparent and traditional PBM, Elixir. We also offer fully integrated mail-order and specialty pharmacy services through Elixir Pharmacy. Additionally, through Elixir Insurance, Elixir also serves one of the fastest-growing demographics in healthcare: seniors enrolled in Medicare Part D. When combined with our retail platform, this comprehensive suite of services allows us to provide value and choice to customers, patients and payors and allows us to compete in today's evolving healthcare marketplace.
Retail Pharmacy Segment
Our Retail Pharmacy segment sells brand and generic prescription drugs and various other pharmacy services, as well as an assortment of front-end products including health and beauty aids, personal care products, seasonal merchandise, and a large private brand product line. Our Retail Pharmacy segment generates the majority of its revenue through the sale of prescription drugs and front-end products at our over 2,400 retail pharmacy locations across 18 states. We replenish our retail stores through a combination of direct store delivery of pharmaceutical products facilitated through our pharmaceutical Purchasing and Delivery Agreement with McKesson, and the majority of our front-end products through our network of distribution centers.
Pharmacy Services Segment
Our Pharmacy Services segment provides a full range of pharmacy benefit services through Elixir. The Pharmacy Services segment provides both transparent and traditional PBM options through its Elixir PBM. Elixir also offers fully integrated mail-order and specialty pharmacy services through Elixir Pharmacy; an innovative claims adjudication software platform in Laker Software; and a national Medicare Part D prescription drug plan through Elixir Insurance’s product offering. The segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, other sponsors of health benefit plans and individuals throughout the United States.
Restructuring
Beginning in Fiscal 2019, we initiated a series of restructuring plans designed to reorganize our executive management team, reduce managerial layers, and consolidate roles. In March 2020, we announced the details of our RxEvolution strategy, which includes building tools to work with regional health plans to improve patient health outcomes, rationalizing SKU’s in our front-end offering to free up working capital and update our merchandise assortment, assessing our pricing and promotional strategy, rebranding our retail pharmacy and pharmacy services business, launching our Store of the Future format and further reducing SG&A and headcount, including integrating certain back office functions in the Pharmacy Services segment both within the segment and across Rite Aid.
As a result of the restructuring that we announced in March 2019, we achieved annual cost savings of approximately $55.0 million. These savings offset the reduction in TSA fees that we experienced in fiscal 2020. We have implemented further restructuring activities in support of our RxEvolution and other initiatives, which resulted in additional restructuring charges due to further reductions in corporate staffing levels, charges associated with rationalizing SKU’s in our front-end offering and other operational changes. These restructuring activities are expected to provide future growth and expense efficiency benefits. We anticipate our total fiscal 2021 restructuring-related costs to be approximately $75.0 million and expect to realize annualized cost savings of approximately $55.0 million over the next two years, as well as benefits to sales, productivity and working capital from our remerchandise initiatives, although a prolonged impact of COVID-19 could impact the amount and timing of the benefit recognized. There can be no
41
assurance that we will not incur additional restructuring charges or that we will achieve the cost savings and remerchandising benefits in the amounts or time anticipated.
Asset Sale to WBA
On September 18, 2017, we entered into the Amended and Restated Asset Purchase Agreement with WBA and Buyer, which amended and restated in its entirety the previously disclosed Original Asset Purchase Agreement. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer purchased from Rite Aid 1,932 Acquired Stores, three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4.375 billion, on a cash-free, debt-free basis, in the Sale. We completed the store transfer process in March of 2018, which resulted in the transfer of all 1,932 stores and related assets to WBA, and received cash proceeds of $4.157 billion.
During fiscal 2019, we completed the sale of one of our distribution centers and related assets to WBA for proceeds of $61.2 million. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $14.2 million, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended March 2, 2019. During fiscal 2020, we completed the sale of the second distribution center and related assets to WBA for proceeds of $62.8 million. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $19.3 million, which has been included in the results of operations and cash flows of discontinued operations during the fifty-two week period ended February 29, 2020. During the first quarter of fiscal 2021, we completed the sale of the final distribution center and related assets to WBA for proceeds of $94.3 million. The impact of the sale of the distribution center and related assets resulted in a pre-tax gain of $12.7 million, which has been included in the results of operations and cash flows of discontinued operations during the thirteen week period ended May 30, 2020. The transfer of the final distribution center and related assets constitutes the final closing under the Amended and Restated Asset Purchase Agreement.
We had agreed to provide transition services to Buyer for up to three years after the initial closing of the Sale. Under the terms of the TSA, we provided various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. The term of the TSA had been extended to October 17, 2020, unless earlier terminated. In connection with these services, we purchased the related inventory and incurred cash payments for the selling, general and administrative activities, which, we billed on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen and twenty-six week periods ended August 29, 2020 were $4.2 million and $35.2 million, respectively, of which $0.0 million is included in Accounts receivable, net. Total billings for these items during the thirteen and twenty-six week periods ended August 31, 2019 were $0.9 billion and $2.1 billion, respectively, of which $196.0 million is included in Accounts receivable, net. We recorded WBA TSA fees of $0.4 million and $1.5 million during the thirteen and twenty-six week periods ended August 29, 2020, respectively, which are reflected as a reduction to selling, general and administrative expenses. We recorded WBA TSA fees of $11.3 million and $25.5 million during the thirteen and twenty-six week periods ended August 31, 2019, respectively, which are reflected as a reduction to selling, general and administrative expenses. In conjunction with the transfer of the final distribution center during the quarter ended May 30, 2020, we have substantially completed our obligations under the TSA. On July 14, 2020, we entered into a letter agreement with WBA to terminate the services under the TSA, other than certain specified services relating to real estate, accounting, tax, and accounts receivable systems that will continue until no later than October 17, 2020 and certain specified services relating to human resources to be performed after October 17, 2020.
Based on its magnitude and because we exited certain markets, the Sale represented a significant strategic shift that has a material effect on our operations and financial results. Accordingly, we have applied discontinued operations treatment for the Sale as required by GAAP.
Overview of Financial Results from Continuing Operations
Our net loss from continuing operations for the thirteen week period ended August 29, 2020 was $13.2 million or $0.25 per basic and diluted share compared to a net loss of $78.7 million or $1.48 per basic and diluted share for the thirteen week period ended August 31, 2019. Our net loss from continuing operations for the twenty-six week period
42
ended August 29, 2020 was $85.9 million or $1.60 per basic and diluted share compared to a net loss of $178.0 million or $3.35 per basic and diluted share for the twenty-six week period ended August 31, 2019. The improvement in net loss for the thirteen and twenty-six week periods ended August 29, 2020 was due primarily to an increase in Adjusted EBITDA, decreases in income tax and interest expense, a LIFO credit in the current year compared to a LIFO charge in the prior year and a gain on debt modification. These benefits were partially offset by higher lease termination and impairment charges caused by the wind down of our RediClinic business. The twenty-six week period ended August 29, 2020 was also impacted by higher intangible asset impairment charges associated with the rebranding of Elixir.
Our Adjusted EBITDA from continuing operations for the thirteen and twenty-six week periods ended August 29, 2020 was $151.6 million or 2.5% of revenues and $259.0 million or 2.2% of revenues, respectively, compared to $134.2 million or 2.5% of revenues and $244.5 million or 2.3% of revenues, respectively, for the thirteen and twenty-six week periods ended August 31, 2019. The increase in Adjusted EBITDA for the thirteen week period ended August 29, 2020 was due to an increase in the Retail Pharmacy segment, partially offset by a decrease in the Pharmacy Services segment. Adjusted EBITDA increased $29.7 million in the Retail Pharmacy segment due primarily to a reduction in SG&A expenses and increased gross profit. SG&A expenses were favorably impacted by changes to modernize our associate paid time off “PTO” plans along with strong expense control. These savings were partially offset by incremental costs associated with the COVID-19 pandemic and the absence of TSA income in the current quarter, as services under that agreement have been completed. Gross profit benefited from increased revenue, partially offset by continued pharmacy reimbursement rate pressures that were not fully offset by generic drug cost reductions. Adjusted EBITDA decreased by $12.3 million in the Pharmacy Services segment due primarily to a reduction of $21.0 million in gross profit related to a change in rebate aggregator at our MedTrak subsidiary. We anticipate that the new rebate aggregator contract will drive improved gross profit for the Company and savings for its clients. The unfavorable gross profit reduction was partially offset by increased revenues, improved pharmacy network management and strong expense control.
The increase in Adjusted EBITDA for the twenty-six week period ended August 29, 2020 was due to an increase in both the Retail Pharmacy and Pharmacy Services segments. Adjusted EBITDA increased $8.6 million in the Retail Pharmacy segment due primarily to a reduction in SG&A expenses and increased gross profit. These benefits were partially offset by incremental costs associated with the COVID-19 pandemic and the completion of services provided under the TSA. Adjusted EBITDA increased by $5.8 million in the Pharmacy Services segment due primarily to increased revenues and improved pharmacy network management, partially offset by reduced rebates resulting from the change in rebate aggregator at our MedTrak subsidiary. Please see the sections entitled “Segment Analysis” and “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” below for additional details.
Consolidated Results of Operations-Continuing Operations
Revenues and Other Operating Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thirteen Week Period Ended |
|
|
Twenty-Six Week Period Ended |
|
|
||||||||
|
|
|
August 29, |
|
August 31, |
|
|
August 29, |
|
August 31, |
|
|
||||
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
|
|
||||
|
|
|
(dollars in thousands except per share amounts) |
|
|
|||||||||||
|
Revenues(a) |
|
$ |
5,981,970 |
|
$ |
5,366,264 |
|
|
$ |
12,009,346 |
|
$ |
10,738,853 |
|
|
|
Revenue growth (decline) |
|
|
11.5 |
% |
|
(1.0) |
% |
|
|
11.8 |
% |
|
(0.7) |
% |
|
|
Net loss |
|
$ |
(13,197) |
|
$ |
(78,705) |
|
|
$ |
(85,899) |
|
$ |
(178,044) |
|
|
|
Net loss per diluted share |
|
$ |
(0.25) |
|
$ |
(1.48) |
|
|
$ |
(1.60) |
|
$ |
(3.35) |
|
|
|
Adjusted EBITDA(b) |
|
$ |
151,603 |
|
$ |
134,190 |
|
|
$ |
258,995 |
|
$ |
244,537 |
|
|
|
Adjusted Net Income (Loss) (b) |
|
$ |
13,536 |
|
$ |
6,288 |
|
|
$ |
11,526 |
|
$ |
(1,231) |
|
|
|
Adjusted Net Income (Loss) per Diluted Share(b) |
|
$ |
0.25 |
|
$ |
0.12 |
|
|
$ |
0.21 |
|
$ |
(0.02) |
|
|
43
| (a) | Revenues for the thirteen and twenty-six week periods ended August 29, 2020 exclude $74,320 and $147,461, respectively, of inter-segment activity that is eliminated in consolidation. Revenues for the thirteen and twenty-six week periods ended August 31, 2019 exclude $60,909 and $119,420, respectively, of inter-segment activity that is eliminated in consolidation. |
| (b) | See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details. |
Revenues
Revenues increased 11.5% and 11.8% for the thirteen and twenty-six weeks ended August 29, 2020, respectively, compared to a decrease of 1.0% and 0.7% for the thirteen and twenty-six weeks ended August 31, 2019. Revenues for the thirteen week period ended August 29, 2020 were positively impacted by a $169.8 million increase in Retail Pharmacy segment revenues and a $459.3 million increase in Pharmacy Services segment revenues. Revenues for the twenty-six week period ended August 29, 2020 were positively impacted by a $428.3 million increase in Retail Pharmacy segment revenues and a $870.3 million increase in Pharmacy Services segment revenues.
Please see the section entitled “Segment Analysis” below for additional details regarding revenues.
Costs and Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thirteen Week Period Ended |
|
|
Twenty-Six Week Period Ended |
|
|
||||||||
|
|
|
August 29, |
|
August 31, |
|
|
August 29, |
|
August 31, |
|
|
||||
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
|
|
||||
|
|
|
(dollars in thousands) |
|
|
|||||||||||
|
Cost of revenues(a) |
|
$ |
4,821,625 |
|
$ |
4,221,825 |
|
|
$ |
9,650,682 |
|
$ |
8,467,691 |
|
|
|
Gross profit |
|
|
1,160,345 |
|
|
1,144,439 |
|
|
|
2,358,664 |
|
|
2,271,162 |
|
|
|
Gross margin |
|
|
19.4 |
% |
|
21.3 |
% |
|
|
19.6 |
% |
|
21.1 |
% |
|
|
Selling, general and administrative expenses |
|
$ |
1,116,142 |
|
$ |
1,135,530 |
|
|
$ |
2,313,289 |
|
$ |
2,298,182 |
|
|
|
Selling, general and administrative expenses as a percentage of revenues |
|
|
18.7 |
% |
|
21.2 |
% |
|
|
19.3 |
% |
|
21.4 |
% |
|
|
Lease termination and impairment charges |
|
|
11,528 |
|
|
1,471 |
|
|
|
15,281 |
|
|
1,949 |
|
|
|
Intangible asset impairment charges |
|
|
— |
|
|
— |
|
|
|
29,852 |
|
|
— |
|
|
|
Interest expense |
|
|
50,007 |
|
|
60,102 |
|
|
|
100,554 |
|
|
118,372 |
|
|
|
Gain on debt modification, net |
|
|
(5,274) |
|
|
— |
|
|
|
(5,274) |
|
|
— |
|
|
|
Loss (gain) on sale of assets, net |
|
|
1,092 |
|
|
(1,587) |
|
|
|
(1,168) |
|
|
(4,299) |
|
|
| (a) | Cost of revenues for the thirteen and twenty-six week periods ended August 29, 2020 exclude $74,320 and $147,461, respectively, of inter-segment activity that is eliminated in consolidation. Cost of revenues for the thirteen and twenty-six week periods ended August 31, 2019 exclude $60,909 and $119,420, respectively, of inter-segment activity that is eliminated in consolidation. |
Gross Profit and Cost of Revenues
Gross profit increased by $15.9 million for the thirteen week period ended August 29, 2020 compared to the thirteen week period ended August 31, 2019. Gross profit increased by $87.5 million for the twenty-six week period ended August 29, 2020 compared to the twenty-six week period ended August 31, 2019. Gross profit for the thirteen week period ended August 29, 2020 includes an increase of $29.5 million in our Retail Pharmacy segment, partially offset by a decrease of $13.6 million in our Pharmacy Services segment. Gross profit for the twenty-six week period ended August 29, 2020 includes an increase of $80.5 million in our Retail Pharmacy segment and an increase of $7.0
44
million in our Pharmacy Services segment. Gross margin was 19.4% for the thirteen week period ended August 29, 2020 compared to 21.3% for the thirteen week period ended August 31, 2019. Gross margin was 19.6% for the twenty-six week period ended August 29, 2020 compared to 21.1% for the twenty-six week period ended August 31, 2019. Please see the section entitled “Segment Analysis” for a more detailed description of gross profit and gross margin results by segment.
Selling, General and Administrative Expenses
SG&A decreased by $19.4 million and increased by $15.1 million for the thirteen and twenty-six week periods ended August 29, 2020, respectively, compared to the thirteen and twenty-six week period ended August 31, 2019. The decrease in SG&A for the thirteen week period ended August 29, 2020 includes a decrease of $14.7 million relating to our Retail Pharmacy segment and a decrease of $4.6 million relating to our Pharmacy Services segment. The increase in SG&A for the twenty-six week period ended August 29, 2020 includes an increase of $22.9 million relating to our Retail Pharmacy segment, partially offset by a decrease of $7.8 million relating to our Pharmacy Services segment. Please see the section entitled “Segment Analysis” below for additional details regarding SG&A.
Lease Termination and Impairment Charges
Lease termination and impairment charges consist of amounts as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thirteen Week |
|
Twenty-Six Week |
||||||||
|
|
|
Period Ended |
|
Period Ended |
||||||||
|
|
|
August 29, |
|
|
August 31, |
|
August 29, |
|
August 31, |
|||
|
|
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||
|
Impairment charges |
|
$ |
9,230 |
|
$ |
1,289 |
|
$ |
11,433 |
|
$ |
1,412 |
|
Lease termination charges |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Facility exit charges |
|
|
2,298 |
|
|
182 |
|
|
3,848 |
|
|
537 |
|
|
|
$ |
11,528 |
|
$ |
1,471 |
|
$ |
15,281 |
|
$ |
1,949 |
During the twenty-six week period ended August 29, 2020, we recorded impairment charges of $11.4 million of which $4.7 relates to a terminated software project and the replacement of existing software, $5.0 million relates to the closure of the remaining RediClinic operations and $1.7 million relates to store and corporate assets.
Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Lease Termination and Impairment Charges” included in our Fiscal 2020 10-K for a detailed description of our impairment and lease termination methodology for fiscal 2020.
Interest Expense
Interest expense was $50.0 million and $100.6 million for the thirteen and twenty-six week periods ended August 29, 2020 respectively, compared to $60.1 million and $118.4 million for the thirteen and twenty-six week periods ended August 31, 2019, respectively. The weighted average interest rate on our indebtedness for the twenty-six week periods ended August 29, 2020 and August 31, 2019 was 4.9% and 5.4%, respectively.
Income Taxes
We recorded an income tax expense from continuing operations of $0.05 million and $27.6 million for the thirteen week periods ended August 29, 2020 and August 31, 2019, respectively. We recorded an income tax benefit from continuing operations of $8.0 million and an income tax expense from continuing operations of $35.0 million for the twenty-six week periods ended August 29, 2020 and August 31, 2019, respectively. The effective tax rate for the thirteen week periods ended August 29, 2020 and August 31, 2019 was (0.4)% and (54.1)%, respectively. The effective tax rate for the twenty-six week periods ended August 29, 2020 and August 31, 2019 was 8.5% and (24.5)%, respectively. The effective tax rate for the thirteen and twenty-six week periods ended August 29, 2020 was net of an adjustment of 7.6% and (8.1)%, respectively, to adjust the valuation allowance against deferred tax assets. The effective tax rate for the thirteen and twenty-six week periods ended August 31, 2019 was net of an adjustment of (78.4)% and (50.2)%, respectively, to increase the valuation allowance against deferred tax assets.
45
We recognize tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.
We believe that it is reasonably possible that a decrease of up to $13.2 million in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.
We regularly evaluate valuation allowances established for deferred tax assets for which future realization is uncertain. We will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. We continue to maintain a valuation allowance against net deferred tax assets of $1,680.1 million and $1,673.1 million, which relates to federal and state deferred tax assets that may not be realized based on our future projections of taxable income at August 29, 2020 and February 29, 2020, respectively.
Segment Analysis
We evaluate the Retail Pharmacy and Pharmacy Services segments’ performance based on revenue, gross profit, and Adjusted EBITDA. The following is a reconciliation of our segments to the condensed consolidated financial statements:
| (1) | Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis. |
(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.
46
Retail Pharmacy Segment Results of Operations
Revenues and Other Operating Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thirteen Week Period Ended |
|
|
Twenty-Six Week Period Ended |
|
|
||||||||
|
|
|
August 29, |
|
August 31, |
|
|
August 29, |
|
August 31, |
|
|
||||
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
|
|
||||
|
|
|
(dollars in thousands) |
|
|
|||||||||||
|
Revenues |
|
$ |
4,017,912 |
|
$ |
3,848,104 |
|
|
$ |
8,141,183 |
|
$ |
7,712,912 |
|
|
|
Revenue growth (decline) |
|
|
4.4 |
% |
|
(1.6) |
% |
|
|
5.6 |
% |
|
(1.2) |
% |
|
|
Same store sales growth |
|
|
3.5 |
% |
|
0.4 |
% |
|
|
5.1 |
% |
|
0.9 |
% |
|
|
Pharmacy sales growth (decline) |
|
|
3.9 |
% |
|
(0.5) |
% |
|
|
3.1 |
% |
|
— |
% |
|
|
Same store prescription count growth, adjusted to 30-day equivalents |
|
|
2.6 |
% |
|
2.7 |
% |
|
|
1.5 |
% |
|
3.2 |
% |
|
|
Same store pharmacy sales growth |
|
|
2.3 |
% |
|
1.5 |
% |
|
|
2.3 |
% |
|
1.9 |
% |
|
|
Pharmacy sales as a % of total retail sales |
|
|
66.8 |
% |
|
67.2 |
% |
|
|
65.5 |
% |
|
67.1 |
% |
|
|
Front-end sales growth (decline) |
|
|
5.7 |
% |
|
(3.8) |
% |
|
|
10.8 |
% |
|
(3.1) |
% |
|
|
Same store front-end sales growth (decline) |
|
|
4.6 |
% |
|
(1.8) |
% |
|
|
9.4 |
% |
|
(1.1) |
% |
|
|
Front-end sales as a % of total retail sales |
|
|
33.2 |
% |
|
32.8 |
% |
|
|
34.5 |
% |
|
32.9 |
% |
|
|
Adjusted EBITDA(*) |
|
$ |
122,340 |
|
$ |
92,673 |
|
|
$ |
185,322 |
|
$ |
176,681 |
|
|
|
Store data: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stores (beginning of period) |
|
|
2,457 |
|
|
2,466 |
|
|
|
2,461 |
|
|
2,469 |
|
|
|
New stores |
|
|
— |
|
|
— |
|
|
|
— |
|
|
1 |
|
|
|
Store acquisitions |
|
|
— |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
Closed stores |
|
|
(7) |
|
|
(2) |
|
|
|
(11) |
|
|
(6) |
|
|
|
Total stores (end of period) |
|
|
2,450 |
|
|
2,464 |
|
|
|
2,450 |
|
|
2,464 |
|
|
|
Relocated stores |
|
|
— |
|
|
1 |
|
|
|
— |
|
|
1 |
|
|
|
Remodeled and expanded stores |
|
|
1 |
|
|
24 |
|
|
|
2 |
|
|
51 |
|
|
(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.
Revenues
Revenues increased 4.4% for the thirteen weeks ended August 29, 2020 compared to a decrease of 1.6% for the thirteen weeks ended August 31, 2019. The increase in revenues for the thirteen week period ended August 29, 2020 was primarily a result of an increase in same store sales.
Pharmacy same store sales increased by 2.3% for the thirteen week period ended August 29, 2020 compared to an increase of 1.5% in the thirteen week period ended August 31, 2019. The increase in pharmacy same store sales is due to the increase in same store prescription count. Same store prescription count, adjusted to 30-day equivalents, increased 2.6% for the thirteen week period ended August 29, 2020 driven by increases in maintenance medication fills, supported by personalized Medication Therapy Management interventions and home deliveries, despite a reduction in acute prescriptions of 4.9%.
Front-end same store sales increased 4.6% during the thirteen week period ended August 29, 2020 compared to a decrease of 1.8% during the thirteen week period ended August 31, 2019. Front-end same store sales, excluding cigarettes and tobacco products, increased 6.1%, driven by increases across a number of categories.
Revenues increased 5.6% for the twenty-six weeks ended August 29, 2020 compared to a decrease of 1.2% for the twenty-six weeks ended August 31, 2019. The increase in revenues for the twenty-six week period ended August 29, 2020 was primarily a result of an increase in same store sales.
Pharmacy same store sales increased by 2.3% for the twenty-six week period ended August 29, 2020 compared to an increase of 1.9% in the twenty-six week period ended August 31, 2019. The increase in pharmacy same store sales
47
is due to the increase in same store prescription count. Same store prescription count, adjusted to 30-day equivalents, increased 1.5% for the twenty-six week period ended August 29, 2020 driven by increases in maintenance medication fills, supported by personalized Medication Therapy Management interventions and home deliveries, partially offset by a reduction in acute prescriptions of 10.0% resulting from the postponement of outpatient medical visits and elective surgical procedures in connection with the COVID-19 pandemic.
Front-end same store sales increased 9.4% during the twenty-six week period ended August 29, 2020 compared to a decrease of 1.1% during the twenty-six week period ended August 31, 2019. Front-end same store sales, excluding cigarettes and tobacco products, increased 11.1%, driven by increases in general cleaning products, sanitizers, wipes, paper products, liquor, over-the-counter products, and summer seasonal items, which were driven by the COVID-19 pandemic.
We include in same store sales all stores that have been open at least one year. Relocation stores are not included in same store sales until one year has lapsed.
Costs and Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thirteen Week Period Ended |
|
|
Twenty-Six Week Period Ended |
|
|
||||||||
|
|
|
August 29, |
|
August 31, |
|
|
August 29, |
|
August 31, |
|
|
||||
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
|
|
||||
|
|
|
(dollars in thousands) |
|
|
|||||||||||
|
Cost of revenues |
|
$ |
2,955,999 |
|
$ |
2,815,660 |
|
|
$ |
5,997,734 |
|
$ |
5,649,973 |
|
|
|
Gross profit |
|
|
1,061,913 |
|
|
1,032,444 |
|
|
|
2,143,449 |
|
|
2,062,939 |
|
|
|
Gross margin |
|
|
26.4 |
% |
|
26.8 |
% |
|
|
26.3 |
% |
|
26.7 |
% |
|
|
FIFO gross profit(*) |
|
|
1,053,163 |
|
|
1,039,948 |
|
|
|
2,122,633 |
|
|
2,077,932 |
|
|
|
FIFO gross margin(*) |
|
|
26.2 |
% |
|
27.0 |
% |
|
|
26.1 |
% |
|
26.9 |
% |
|
|
Selling, general and administrative expenses |
|
$ |
1,030,075 |
|
$ |
1,044,818 |
|
|
|
2,139,051 |
|
|
2,116,143 |
|
|
|
Selling, general and administrative expenses as a percentage of revenues |
|
|
25.6 |
% |
|
27.2 |
% |
|
|
26.3 |
% |
|
27.4 |
% |
|
(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.
Gross Profit and Cost of Revenues
Gross profit increased $29.5 million for the thirteen week period ended August 29, 2020 compared to the thirteen week period ended August 31, 2019, driven by higher front-end sales volume and an increase in maintenance prescriptions, partially offset by a reduction in acute prescriptions and continued pharmacy reimbursement rate pressure.
Gross profit increased $80.5 million for the twenty-six week period ended August 29, 2020 compared to the twenty-six week period ended August 31, 2019, driven by an increase in front-end gross profit resulting from the increase in same store sales, partially offset by a restructuring charge of $25.8 million to establish an inventory reserve on product lines we are exiting and will no longer carry as part of our rebranding initiative and continued pharmacy reimbursement rate pressure.
Gross margin was 26.4% of sales for the thirteen week period ended August 29, 2020 compared to 26.8% of sales for the thirteen week period ended August 31, 2019. The decline in gross margin as a percentage of revenues is due primarily to continued pharmacy reimbursement rate pressure.
Gross margin was 26.3% of sales for the twenty-six week period ended August 29, 2020 compared to 26.7% of sales for the twenty-six week period ended August 31, 2019. The decline in gross margin as a percentage of revenues is due primarily to higher markdowns related to increased sales volume to our wellness+ members, continued pharmacy reimbursement rate pressures and higher discounts on front-end merchandise provided to our associates in response to the COVID-19 pandemic.
48
We use the last-in, first-out (“LIFO”) method of inventory valuation, which is estimated on a quarterly basis and is finalized at year end when inflation rates and inventory levels are final. Therefore, LIFO costs for interim period financial statements are estimated. LIFO credits were $8.8 million and $20.8 million for the thirteen and twenty-six week periods ended August 29, 2020, respectively, compared to LIFO charges of $7.5 million and $15.0 million for the thirteen and twenty-six week periods ended August 31, 2019, respectively. The LIFO credit in the thirteen week period ended August 29, 2020 was mostly due to the planned reduction in front-end inventory resulting from our rebranding initiative and lower expected pharmacy inflation.
Selling, General and Administrative Expenses
SG&A expenses decreased $14.7 million and 1.6% as a percentage of revenues for the thirteen week period ended August 29, 2020 due primarily to changes to modernize our associate PTO plans and strong expense control. These savings were partially offset by incremental costs associated with the COVID-19 pandemic and the absence of TSA income in the current quarter, as services under that agreement have been completed.
SG&A expenses increased $22.9 million for the twenty-six week period ended August 29, 2020 due primarily to a reduction in WBA TSA fees and the current year incurrence of COVID-19 related expenses, including our Hero Pay and Hero Bonus programs, store cleaning and sanitation and related measures to keep our associates and customers safe, partially offset by the changes to modernize our associate PTO plans. SG&A expenses as a percentage of revenues for the twenty-six week period ended August 29, 2020 was 26.3% compared to 27.4% for the twenty-six week period ended August 31, 2019 due to the associate PTO plan change and increased sales leverage, partially offset by higher COVID-19 related expenses.
Pharmacy Services Segment Results of Operations
Revenues and Other Operating Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
Thirteen Week Period Ended |
|
|
Twenty-Six Week Period Ended |
|
|
||||||||
|
|
|
August 29, |
|
August 31, |
|
|
August 29, |
|
August 31, |
|
|
||||
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
|
|
||||
|
|
|
(dollars in thousands) |
|
|
|||||||||||
|
Revenues |
|
$ |
2,038,378 |
|
$ |
1,579,069 |
|
|
$ |
4,015,624 |
|
$ |
3,145,361 |
|
|
|
Revenue growth |
|
|
29.1 |
% |
|
1.1 |
% |
|
|
27.7 |
% |
|
1.3 |
% |
|
|
Adjusted EBITDA(*) |
|
$ |
29,263 |
|
$ |
41,517 |
|
|
$ |
73,673 |
|
$ |
67,856 |
|
|
(*) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.
Revenues
Pharmacy Services segment revenues for the thirteen week period ended August 29, 2020 were $2,038.4 million as compared to revenues of $1,579.1 million for the thirteen week period ended August 31, 2019. Pharmacy Services segment revenues for the twenty-six week period ended August 29, 2020 were $4,015.6 million as compared to revenues of $3,145.4 million for the twenty-six week period ended August 31, 2019. The increase in revenues for the segment is primarily due to an increase in Medicare Part D membership.
49
Costs and Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
Thirteen Week Period Ended |
|
|
Twenty-Six Week Period Ended |
|
|
||||||||
|
|
|
August 29, |
|
August 31, |
|
|
August 29, |
|
August 31, |
|
|
||||
|
|
|
2020 |
|
2019 |
|
|
2020 |
|
2019 |
|
|
||||
|
|
|
(dollars in thousands) |
|
|
|||||||||||
|
Cost of revenues |
|
$ |
1,939,946 |
|
$ |
1,467,074 |
|
|
$ |
3,800,409 |
|
$ |
2,937,138 |
|
|
|
Gross profit |
|
|
98,432 |
|
|
111,995 |
|
|
|
215,215 |
|
|
208,223 |
|
|
|
Gross margin |
|
|
4.8 |
% |
|
7.1 |
% |
|
|
5.4 |
% |
|
6.6 |
% |
|
|
Selling, general and administrative expenses |
|
$ |
86,067 |
|
$ |
90,712 |
|
|
|
174,238 |
|
|
182,039 |
|
|
|
Selling, general and administrative expenses as a percentage of revenues |
|
|
4.2 |
% |
|
5.7 |
% |
|
|
4.3 |
% |
|
5.8 |
% |
|
Gross Profit and Cost of Revenues
Gross profit for the thirteen week period ended August 29, 2020 was $98.4 million as compared to gross profit of $112.0 million for the thirteen week period ended August 31, 2019. Gross profit for the twenty-six week period ended August 29, 2020 was $215.2 million as compared to gross profit of $208.2 million for the twenty-six week period ended August 31, 2019. The decrease in the thirteen week period gross profit for the segment is primarily due to a change in rebate aggregator at our MedTrak subsidiary. We anticipate that the new rebate aggregator contract will drive improved gross profit for the company and savings for its clients. The reduction was partially offset by increased revenues and improved pharmacy network management. The increase in the twenty-six week period gross profit for the segment is primarily due to increased revenues and improved pharmacy network management.
Gross margin was 4.8% of sales for the thirteen week period ended August 29, 2020 compared to 7.1% of sales for the thirteen week period ended August 31, 2019. Gross margin was 5.4% of sales for the twenty-six week period ended August 29, 2020 compared to 6.6% of sales for the twenty-six week period ended August 31, 2019. The decline in gross margin is due primarily to an increase in Medicare Part D membership and the change in rebate aggregator at our MedTrak subsidiary.
Selling, General and Administrative Expenses
Pharmacy Services segment selling, general and administrative expenses for the thirteen week period ended August 29, 2020 was $86.1 million as compared to $90.7 million for the thirteen week period ended August 31, 2019. Pharmacy Services segment selling, general and administrative expenses for the twenty-six week period ended August 29, 2020 was $174.2 million as compared to $182.0 million for the twenty-six week period ended August 31, 2019. Selling, general and administrative expenses as a percentage of Pharmacy Services segment revenue was 4.2% and 5.7% for the thirteen week periods ended August 29, 2020 and August 31, 2019, respectively. Selling, general and administrative expenses as a percentage of Pharmacy Services segment revenue was 4.3% and 5.8% for the twenty-six week periods ended August 29, 2020 and August 31, 2019, respectively. The decrease in the thirteen and twenty-six week periods selling, general and administrative expenses is primarily the result of expense control initiatives, partially offset by higher costs associated with supporting the increased Medicare Part D membership.
Liquidity and Capital Resources
General
We have two primary sources of liquidity: (i) cash provided by operating activities and (ii) borrowings under the Existing Facilities. Our principal uses of cash are to provide working capital for operations, to service our obligations to pay interest and principal on debt and to fund capital expenditures. Total liquidity as of August 29, 2020 was $1,348.1 million, which consisted of revolver borrowing capacity of $1,297.1 million and invested cash of $51.0 million.
50
Credit Facilities
On December 20, 2018, we entered into a senior secured credit agreement (as amended by the First Amendment to Credit Agreement, dated as of January 6, 2020, the “Credit Agreement”), consisting of a $2.7 billion senior secured asset-based revolving credit facility (“Senior Secured Revolving Credit Facility”) and a $450.0 million “first-in, last out” senior secured term loan facility (“Senior Secured Term Loan,” and together with the Senior Secured Revolving Credit Facility, collectively, the “Existing Facilities”). We used proceeds from the Existing Facilities to refinance our prior $2.7 billion existing credit agreement (the “Old Facility”). The Existing Facilities extend our debt maturity profile and provide additional liquidity. Borrowings under the Senior Secured Revolving Credit Facility bear interest at a rate per annum between LIBOR plus 1.25% and LIBOR plus 1.75% based upon the Average ABL Availability (as defined in the Credit Agreement). Borrowings under the Senior Secured Term Loan bear interest at a rate per annum of LIBOR plus 3.00%. We are required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the commitments under the Senior Secured Revolving Credit Facility, depending on Average ABL Availability. The Existing Facilities mature on December 20, 2023, subject to an earlier maturity on December 31, 2022 if we have not repaid or refinanced our existing 6.125% Notes prior to such date. We have been engaged in efforts to refinance our existing 6.125% Notes and we intend to repay or refinance any of such outstanding notes prior to the early maturity becoming effective, although we cannot assure you what impact the recent disruption in the financial markets will have on any such efforts.
Our borrowing capacity under the Senior Secured Revolving Credit Facility is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At August 29, 2020, we had approximately $1,750.0 million of borrowings outstanding under the Existing Facilities and had letters of credit outstanding against the Senior Secured Revolving Credit Facility of approximately $102.9 million, which resulted in additional borrowing capacity under the Senior Secured Revolving Credit Facility of $1,297.1 million. If at any time the total credit exposure outstanding under the Existing Facilities and the principal amount of our other senior obligations exceed the borrowing base, we will be required to make certain other mandatory prepayments to eliminate such shortfall.
The Credit Agreement restricts us and all of our subsidiaries, including the subsidiaries that guarantee our obligations under the Existing Facilities, the secured guaranteed notes and unsecured guaranteed notes (collectively, the “Subsidiary Guarantors”) from accumulating cash on hand in excess of $200.0 million at any time when revolving loans are outstanding (not including cash located in our store and lockbox deposit accounts and cash necessary to cover our current liabilities). The Credit Agreement also states that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default exists under the Existing Facilities or (ii) the sum of our borrowing capacity under our Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account is less than $275.0 million for three consecutive business days or less than or equal to $200.0 million on any day (a “cash sweep period”), the funds in our deposit accounts will be swept to a concentration account with the senior collateral agent and will be applied first to repay outstanding revolving loans under the Existing Facilities, and then held as collateral for the senior obligations until such cash sweep period is rescinded pursuant to the terms of the Existing Facilities.
Our obligations under the Existing Facilities and the Subsidiary Guarantors’ obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivable, inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of their deposit accounts, collectively, the “ABL priority collateral”) and (ii) a second-priority lien on all of the Subsidiary Guarantors’ equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and all other assets that do not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations.
The Credit Agreement allows us to have outstanding, at any time, up to an aggregate principal amount of $1.5 billion in secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Existing Facilities and other existing indebtedness, provided that not in excess of $750.0 million of such secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock
51
shall mature or require scheduled payments of principal prior to 90 days after the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the Credit Agreement) (excluding bridge facilities allowing extensions on customary terms to at least the date that is 90 days after such date). Subject to the limitations described in the immediately preceding sentence, the Credit Agreement additionally allows us to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Credit Agreement) is not in effect; provided, however, that certain of our other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Credit Agreement also contains certain restrictions on the amount of secured first priority debt we are able to incur. The Credit Agreement also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Existing Facilities are not in default and we maintain availability under our revolver of more than $365.0 million.
The Credit Agreement has a financial covenant that requires us to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the Senior Secured Revolving Credit Facility is less than $200.0 million or (ii) on the third consecutive business day on which availability under the Senior Secured Revolving Credit Facility is less than $250.0 million and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $250.0 million. As of August 29, 2020, our fixed charge coverage ratio was greater than 1.00 to 1.00, and we were in compliance with the Credit Agreement’s financial covenant. The Credit Agreement also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, the making of investments, sale of assets, mergers and acquisitions and the granting of liens.
The Credit Agreement provides for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if we fail to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurs that enables, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment repurchase, redemption or defeasance of such debt.
The indentures that govern our guaranteed unsecured notes and our guaranteed secured notes contain restrictions on the amount of additional secured and unsecured debt that we may incur. As of August 29, 2020, we had the ability to (i) draw the full amount under our revolving credit facility, or (ii) incur additional secured debt. In addition, we have the ability to enter into certain sale and leaseback transactions. The ability to issue additional unsecured debt under the indenture is generally governed by an interest coverage ratio test. As of August 29, 2020, we had the ability to issue additional secured and unsecured debt under the indentures governing our unguaranteed unsecured notes.
Guarantor Summarized Financial Information
Certain of our subsidiaries, which are listed on Exhibit 22 to this Quarterly Report on Form 10-Q, have guaranteed our obligations under the 6.125% Notes and the 7.500% Notes (collectively, the "Guaranteed Notes"). As discussed in Note 11 to the consolidated financial statements, the Guaranteed Notes were issued by us, as the parent company, and are guaranteed by substantially all of the parent company’s consolidated subsidiaries (the “guarantors” or “Subsidiary Guarantors”) except for EIC (the “non-guarantor”). The parent company and guarantors are referred to as the “obligor group”. The Subsidiary Guarantors fully and unconditionally and jointly and severally guarantee the Guaranteed Notes. The 6.125% Notes and the obligations under the related guarantees are unsecured. The 7.500% Notes and the obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors’ equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and other collateral to the extent it does not constitute ABL priority collateral (as defined below), and (ii) a second-priority lien on all of the Subsidiary Guarantors’ cash and cash equivalents, accounts receivables, payment intangibles, inventory, prescription files (including eligible script lists) and, intellectual property (prior to the repayment of the Senior Secured Term Loan) (collectively, the “ABL priority collateral”), which, in each case, also secure the Existing Facilities.
Under certain circumstances, subsidiaries may be released from their guarantees without consent of the note holders. Our subsidiaries conduct substantially all of our operations and have significant liabilities, including trade
52
payables. If the subsidiary guarantees are invalid or unenforceable or are limited by fraudulent conveyance or other laws, the registered debt will be structurally subordinated to the substantial liabilities of our subsidiaries.
Condensed Combined Financial Information
The following tables include summarized financial information of the obligor group. Investments in and the equity in the earnings of EIC, which is not a member of the obligor group, have been excluded. The summarized financial information of the obligor group is presented on a combined basis with intercompany balances and transactions between entities in the obligor group eliminated. The obligor group’s amounts due to/from and transactions with EIC have been presented in separate line items, if material.
| (a) | Includes $21.7 million and $36.0 million of revenues generated from the non-guarantor for the thirteen and twenty-six week periods ended August 29, 2020, respectively. |
| (b) | Includes $21.7 million and $36.0 million of cost of revenues incurred in transactions with the non-guarantor for the thirteen and twenty-six week periods ended August 29, 2020, respectively. |
Net Cash Provided by/Used in Operating, Investing and Financing Activities
Cash used in operating activities was $476.6 million and $330.0 million for the twenty-six week periods ended August 29, 2020 and August 31, 2019, respectively. Operating cash flow was negatively impacted by the growth in our
53
Calendar 2020 Medicare Part D receivable, timing differences in the receipt of our monthly capitation payment from CMS, timing of receipts from pharmacy third-party payors, and lower employee benefit related accruals and wellness+ deferral, partially offset by the $52.7 million benefit from the payroll tax deferral under the CARES act and higher accrued liabilities relating to Elixir’s pharmacy network due to timing.
Cash used in investing activities was $58.8 million and $95.3 million for the twenty-six week periods ended August 29, 2020 and August 31, 2019, respectively. Cash used for the purchase of property, plant, and equipment was lower than the prior year due to less store remodels in the current year. During the twenty-six week period ended August 29, 2020, we remodeled two stores and spent $22.6 million on prescription file purchases. Proceeds from insured loss includes cash proceeds associated with civil unrest.
Cash flow provided by financing activities was $397.8 million and $425.0 million for the twenty-six week periods ended August 29, 2020 and August 31, 2019, respectively. Cash provided by financing activities for the twenty-six weeks ended August 29, 2020 reflects net revolver borrowings, in addition to borrowings to facilitate the June 25, 2020 Exchange Offer.
Capital Expenditures
During the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019 capital expenditures were as follows:
Future Liquidity
We are highly leveraged. Our high level of indebtedness could: (i) limit our ability to obtain additional financing; (ii) limit our flexibility in planning for, or reacting to, changes in our business and the industry; (iii) place us at a competitive disadvantage relative to our competitors with less debt; (iv) render us more vulnerable to general adverse economic and industry conditions, including those resulting from COVID-19; and (v) require us to dedicate a substantial portion of our cash flow to service our debt. Based upon our current levels of operations, we believe that cash flow from operations together with available borrowings under the revolver and other sources of liquidity will be adequate to meet our requirements for working capital, debt service, capital expenditures and other strategic investments at least for the next twelve months. Based on our liquidity position, which we expect to remain strong, we do not expect to be subject to the minimum fixed charge covenant in the Existing Facilities in the next twelve months. We will continue to assess our liquidity position and potential sources of supplemental liquidity in light of our operating performance, and other relevant circumstances, and we may evaluate alternative sources of liquidity, including further opportunities related to any receivable due to us from CMS, sale and leaseback transactions, and other transactions to optimize our asset base. From time to time, we may seek additional deleveraging or refinancing transactions, including entering into transactions to exchange debt for shares of common stock or other debt securities (including additional secured debt), issuance of equity (including preferred stock and convertible securities), repurchase or redemption of outstanding indebtedness, or seek to refinance our outstanding debt (including the Existing Facilities) or may otherwise seek transactions to reduce interest expense and extend debt maturities. We may also look to make additional investments in our business to further our strategic objectives, including targeted acquisitions. Any of these transactions could impact our financial results.
54
Critical Accounting Policies and Estimates
For a description of the critical accounting policies that require the use of significant judgments and estimates by management, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations—Critical Accounting Policies and Estimates” included in our Fiscal 2020 10-K, which we filed with the SEC on April 27, 2020.
Factors Affecting Our Future Prospects
For a discussion of risks related to our financial condition, operations and industry, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations” included herein and in our Fiscal 2020 10-K, “Part I – Item 1A. Risk Factors” in our Fiscal 2020 10-K and “Part II – Item 1A. Risk Factors” in our First Quarter Fiscal 2021 10-Q.
Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures
In addition to net income (loss) determined in accordance with GAAP, we use certain non-GAAP measures, such as “Adjusted EBITDA”, in assessing our operating performance. We believe the non-GAAP measures serve as an appropriate measure in evaluating the performance of our business. We define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), charges or credits for facility closing and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt retirements and modifications, the WBA merger termination fee, and other items (including stock-based compensation expense, merger and acquisition-related costs, a non-recurring litigation settlement, severance, restructuring-related costs and costs related to facility closures and gain or loss on sale of assets). We reference this particular non-GAAP financial measure frequently in our decision-making because it provides supplemental information that facilitates internal comparisons to the historical periods and external comparisons to competitors. In addition, incentive compensation is primarily based on Adjusted EBITDA and we base certain of our forward-looking estimates on Adjusted EBITDA to facilitate quantification of planned business activities and enhance subsequent follow-up with comparisons of actual to planned Adjusted EBITDA.
55
The following is a reconciliation of our net loss to Adjusted EBITDA for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019:
The following is a reconciliation of our net income (loss) from continuing operations to Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share for the thirteen and twenty-six week periods ended August 29, 2020 and August 31, 2019. Adjusted Net Income (Loss) is defined as net income (loss) excluding the impact of amortization expense, merger and acquisition-related costs, a non-recurring litigation settlement, gains or losses on debt retirements and modifications, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), goodwill and intangible asset impairment charges, restructuring-related costs and the WBA merger termination fee. We calculate Adjusted Net Income (Loss) per Diluted Share using our above-referenced definition of Adjusted Net Income (Loss). We believe Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share are useful indicators of our operating performance over multiple periods. Adjusted Net Income (Loss) per Diluted Share is calculated using our above-referenced definition of Adjusted Net Income (Loss):
56
| (a) | The fiscal year 2021 and 2020 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL’s, state credits and valuation allowance, was used for the thirteen and twenty-six weeks ended August 29, 2020 and August 31, 2019, respectively. |
In addition to Adjusted EBITDA, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share, we occasionally refer to several other Non-GAAP measures, on a less frequent basis, in order to describe certain components of our business and how we utilize them to describe our results. These measures include but are not limited to Adjusted EBITDA Gross Margin and Gross Profit (gross margin/gross profit excluding non-Adjusted EBITDA items), Adjusted EBITDA SG&A (SG&A expenses excluding non-Adjusted EBITDA items), FIFO Gross Margin and FIFO Gross Profit (gross margin/gross profit before LIFO charges), and Free Cash Flow (Adjusted EBITDA less cash paid for interest, rent on closed stores, capital expenditures, acquisition costs and the change in working capital).
We include these non-GAAP financial measures in our earnings announcements in order to provide transparency to our investors and enable investors to better compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share or other non-GAAP measures should not be considered in isolation from, and are not intended to represent an alternative measure of, operating results or of cash flows from operating activities, as determined in accordance with GAAP. Our definition of these non-GAAP measures may not be comparable to similarly titled measurements reported by other companies.
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
Our future earnings, cash flow and fair values relevant to financial instruments are dependent upon prevalent market rates. Market risk is the risk of loss from adverse changes in market prices and interest rates. Our major market risk exposure is changing interest rates. Increases in interest rates would increase our interest expense. We enter into debt obligations to support capital expenditures, acquisitions, working capital needs and general corporate purposes. Our policy is to manage interest rates through the use of a combination of variable-rate credit facilities, fixed-rate long-term obligations and derivative transactions.
The table below provides information about our financial instruments that are sensitive to changes in interest rates. The table presents principal payments and the related weighted average interest rates by expected maturity dates as of August 29, 2020 and assumes that we have repaid or refinanced our existing 6.125% Notes prior to December 31, 2022.
Our ability to satisfy interest payment obligations on our outstanding debt will depend largely on our future performance, which, in turn, is subject to prevailing economic conditions and to financial, business and other factors beyond our control. If we do not have sufficient cash flow to service our interest payment obligations on our outstanding indebtedness and if we cannot borrow or obtain equity financing to satisfy those obligations, our business and results of operations could be materially adversely affected. We cannot be assured that any replacement borrowing or equity financing could be successfully completed.
The interest rate on our variable rate borrowings, which include our revolving credit facility and our term loan facility, are based on LIBOR. If the market rates of interest for LIBOR changed by 100 basis points as of August 29, 2020, our annual interest expense would change by approximately $17.5 million.
57
A change in interest rates does not have an impact upon our future earnings and cash flow for fixed-rate debt instruments. As fixed-rate debt matures, however, and if additional debt is acquired to fund the debt repayment, future earnings and cash flow may be affected by changes in interest rates. This effect would be realized in the periods subsequent to the periods when the debt matures. Increases in interest rates would also impact our ability to refinance existing maturities on favorable terms.
ITEM 4. Controls and Procedures
(a) Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective.
(b) Changes in Internal Control over Financial Reporting
There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
58
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings
The information in response to this item is incorporated herein by reference to Note 16, Commitments, Contingencies and Guarantees, of the Consolidated Condensed Financial Statements of this Quarterly Report.
ITEM 1A. Risk Factors
In addition to the information set forth in this Quarterly Report, you should carefully consider the factors discussed in “Part I — Item 1A. Risk Factors” in our Fiscal 2020 10-K and in “Part II – Item 1A. Risk Factors” in our First Quarter Fiscal 2021 Form 10-Q, which could materially affect our business, financial condition or future results.
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities. The table below is a listing of repurchases of common stock during the second quarter of fiscal 2021.
ITEM 3. Defaults Upon Senior Securities
Not applicable.
ITEM 4. Mine Safety Disclosures
Not applicable.
ITEM 5. Other Information
Not applicable.
ITEM 6. Exhibits
| (a) | The following exhibits are filed as part of this report. |
59
60
|
|
|
|
|
|
|---|---|---|---|---|
|
Exhibit
|
|
Description |
|
Incorporation By Reference To |
|
4.11 |
|
|
Exhibit 4.3 to Form 8-K filed on July 27, 2020 |
|
|
10.1 |
|
|
Exhibit 10.1 to Form 8-K, filed on June 25, 2010 |
|
|
10.2 |
|
Amendment No. 1, dated September 21, 2010, to the 2010 Omnibus Equity Plan |
|
Exhibit 10.7 to Form 10-Q, filed on October 7, 2010 |
|
10.3 |
|
Amendment No. 2, dated January 16, 2013, to the 2010 Omnibus Equity Plan |
|
Exhibit 10.8 to Form 10-K, filed on April 23, 2013 |
|
10.4 |
|
|
Exhibit 10.1 to Form 8-K, filed on June 25, 2012 |
|
|
10.5 |
|
Amendment No. 1, dated January 16, 2013, to the 2012 Omnibus Equity Plan |
|
Exhibit 10.10 to Form 10-K, filed on April 23, 2013 |
|
10.6 |
|
|
Exhibit 10.1 to Form 8-K, filed on June 23, 2014 |
|
|
10.7 |
|
|
Exhibit 10.2 to Form 8-K, filed on May 15, 2012 |
|
|
10.8 |
|
|
Exhibit 10.6 to Form 10-K, filed on April 28, 2010 |
|
|
10.9 |
|
Executive Incentive Plan for Officers of Rite Aid Corporation |
|
Exhibit 10.1 to Form 8-K, filed on February 24, 2012 |
|
10.10 |
|
|
Exhibit 10.7 to Form 10-K, filed on April 28, 2010 |
|
|
10.11 |
|
|
Exhibit 10.2 to Form 10-Q, filed on October 2, 2014 |
|
|
10.12 |
|
|
Exhibit 10.1 to Form 8-K, filed on October 28, 2015 |
|
|
10.13 |
|
|
Exhibit 10.1 to Form 10-Q, filed on January 6, 2016 |
|
|
10.14 |
|
Employment Agreement by and between Rite Aid Corporation and Bryan Everett dated as of June 22, 2015 |
|
Exhibit 10.2 to Form 10-Q, filed on January 6, 2016 |
|
10.15 |
|
|
Exhibit 10.1 to Form 8-K, filed on January 7, 2016 |
|
|
10.16 |
|
|
Exhibit 10.2 to Form 8-K, filed on January 7, 2016 |
|
|
10.17 |
|
|
Exhibit 10.1 to Form 8-K, filed on December 20, 2018 |
61
|
|
|
|
|
|
|---|---|---|---|---|
|
Exhibit
|
|
Description |
|
Incorporation By Reference To |
|
10.18 |
|
|
Exhibit 10.3 to Form 8-K, filed on June 11, 2009 |
|
|
|
|
|
|
|
|
10.19 |
|
|
Exhibit 10.27 to Form 10-K, filed on April 25, 2019 |
|
|
10.20 |
|
|
Exhibit 10.28 to Form 10-Q, filed on July 11, 2019 |
|
|
10.21 |
|
|
Exhibit 10.29 to Form 10-Q, filed on July 11, 2019 |
|
|
10.22 |
|
|
Exhibit 10.30 to Form 10-Q, filed on July 11, 2019 |
|
|
10.23 |
|
|
Exhibit 10.31 to Form 10-Q, filed on July 11, 2019 |
|
|
10.24 |
|
|
Exhibit 10.32 to Form 10-Q, filed on July 11, 2019 |
|
|
10.25 |
|
|
Exhibit 10.33 to Form 10-Q, filed on July 11, 2019 |
|
|
10.26 |
|
|
Exhibit 10.34 to Form 10-Q, filed on July 11, 2019 |
|
|
10.27 |
|
|
Exhibit 10.35 to Form 10-Q, filed on July 11, 2019 |
|
|
10.28 |
|
|
Exhibit 10.36 to Form 10-Q, filed on July 11, 2019 |
|
|
10.29 |
|
|
Exhibit 10.37 to Form 10-Q, filed on July 11, 2019 |
|
|
10.30 |
|
|
Exhibit 10.38 to Form 10-Q, filed on July 11, 2019 |
|
|
10.31 |
|
Employment Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August 8, 2019** |
|
Exhibit 10.1 to Form 8-K, filed on August 12, 2019 |
|
10.32 |
|
|
Exhibit 10.2 to Form 8-K, filed on August 12, 2019 |
62
|
|
|
|
|
|
|---|---|---|---|---|
|
Exhibit
|
|
Description |
|
Incorporation By Reference To |
|
10.33 |
|
|
Exhibit 10.1 to Form 8-K, filed on August 16, 2019 |
|
|
10.34 |
|
Employment Agreement dated October 2, 2019 by and between Rite Aid Corporation and James Peters |
|
Exhibit 10.1 to Form 8-K, filed on October 2, 2019 |
|
10.35 |
|
Separation Agreement dated October 2, 2019 by and between Rite Aid Corporation and Bryan Everett |
|
Exhibit 10.2 to Form 8-K, filed on October 2, 2019 |
|
10.36 |
|
Consulting Agreement dated October 2, 2019 by and between Rite Aid Corporation and Bryan Everett |
|
Exhibit 10.3 to Form 8-K, filed on October 2, 2019 |
|
10.37 |
|
|
Exhibit 10.41 to Form 10-K filed on April 27, 2020 |
|
|
10.38 |
|
Amendment to Employment Agreement by and between James J. Comitale, dated November 6, 2019 |
|
Exhibit 10.42 to Form 10-K filed on April 27, 2020 |
|
10.39 |
|
|
Exhibit 10.43 to Form 10-K filed on April 27, 2020 |
|
|
10.40 |
|
Amendment to Employment Agreement by and between Jessica Kazmaier, dated November 6, 2019 |
|
Exhibit 10.44 to Form 10-K filed on April 27, 2020 |
|
10.41 |
|
Employment Agreement by and between Justin Mennen, dated as of December 7, 2018 |
|
Exhibit 10.45 to Form 10-K filed on April 27, 2020 |
|
10.42 |
|
Amendment to Employment Agreement by and between Justin Mennen, dated November 6, 2019 |
|
Exhibit 10.46 to Form 10-K filed on April 27, 2020 |
|
10.43 |
|
|
Exhibit 10.47 to Form 10-K filed on April 27, 2020 |
|
|
10.44 |
|
Employment Agreement by and between RxOptions, LLC and Dan Robson, dated as of December 12, 2019 |
|
Exhibit 10.48 to Form 10-K filed on April 27, 2020 |
|
10.45 |
|
Separation Agreement by and between Rite Aid Corporation and James C. Comitale, as of May 21, 2020 |
|
Exhibit 10.45 to Form 10-Q filed on July 2, 2020 |
|
10.46 |
|
Employment Agreement by and between Rite Aid Corporation and Paul D. Gilbert, as of July 29, 2020 |
|
Filed herewith |
|
22 |
|
|
Filed herewith |
|
|
31.1 |
|
|
Filed herewith |
|
|
31.2 |
|
|
Filed herewith |
|
|
32 |
|
|
Filed herewith |
|
|
101.INS |
|
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
|
Filed herewith |
|
101.SCH |
|
XBRL Taxonomy Extension Schema Document. |
|
Filed herewith |
|
101.CAL |
|
XBRL Taxonomy Extension Calculation Linkbase Document. |
|
Filed herewith |
|
101.DEF |
|
XBRL Taxonomy Extension Definition Linkbase Document. |
|
Filed herewith |
|
101.LAB |
|
XBRL Taxonomy Extension Label Linkbase Document. |
|
Filed herewith |
|
101.PRE |
|
XBRL Taxonomy Extension Presentation Linkbase Document. |
|
Filed herewith |
|
104 |
|
Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
|
Filed herewith |
* Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(10) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.
63
** Certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.
64
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
Date: October 6, 2020 |
RITE AID CORPORATION |
|
|
|
|
|
|
|
By: |
/s/ MATTHEW C. SCHROEDER |
|
|
|
Matthew C. Schroeder |
|
|
|
Executive Vice President and Chief Financial Officer |
|
|
|
|
|
Date: October 6, 2020 |
By: |
/s/ BRIAN T. HOOVER |
|
|
|
Brian T. Hoover |
|
|
|
Senior Vice President and Chief Accounting Officer |
65
Exhibit 10.46
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 29th day of July, 2020, by and between Rite Aid Corporation, a Delaware corporation (the “Company”) and Paul D. Gilbert (“Executive”).
WHEREAS, the Company desires to employ Executive and Executive desires to provide the Company with Executive’s services subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive (individually a “Party” and together the “Parties”), intending to be legally bound, agree as follows:
The term of Executive’s employment under this Agreement shall commence on August 17, 2020 (the “Effective Date”) and, unless earlier terminated pursuant to Section 5 below, shall continue for a period ending on the date that is two (2) years following the Effective Date (the “Original Term of Employment”). The Original Term of Employment shall be automatically renewed for successive one (1) year terms (the “Renewal Terms”) unless at least one hundred twenty (120) days prior to the expiration of the Original Term of Employment or any Renewal Term, either Party notifies the other Party in writing that Executive or it is electing to terminate this Agreement at the expiration of the then current Term of Employment. “Term” shall mean the Original Term of Employment and all Renewal Terms. For purposes of this Agreement, except as otherwise provided herein, the phrases “year during the Term” or similar language shall refer to each twelve (12) month period commencing on the Effective Date or applicable anniversaries thereof.
the board of directors of one other for-profit corporation or the boards of a reasonable number of trade associations and/or charitable organizations, in each case subject to the Company’s approval, which shall not be unreasonably withheld, (ii) engaging in charitable activities and community affairs, and (iii) managing Executive’s personal investments and affairs, provided that Executive’s activities pursuant to clauses (i), (ii) or (iii) do not violate Sections 6 or 7 below or materially interfere with the proper performance of Executive’s duties and responsibilities under this Agreement. Executive shall at all times be subject to, observe and carry out such rules, regulations, policies, directions, and restrictions as the Company may from time to time establish for officers of the Company or employees generally.
2
3
4
Any termination of Executive’s employment by Executive voluntarily without Good Reason shall be effective upon a thirty (30) day notice to the Company or such earlier date as the Company determines in its discretion and designates in writing. A good faith termination of Executive’s employment by the Company for Cause or by the Executive other than for Good Reason shall not constitute a breach of this Agreement.
5
Any termination of employment pursuant to this Section 5.3 shall be effective upon a thirty (30) day notice thereof or the Company may elect in its sole discretion to reduce or eliminate the notice period and pay the Executive’s Base Salary for some or all of the notice period in lieu of notice. A termination of Executive’s employment by the Company other than for Cause or by the Executive for Good Reason shall not constitute a breach of this Agreement. To be eligible for the payment, benefits and stock rights described in Section 5.3(a)(ii) and (iii), (b) and (c) above, Executive must execute within sixty (60) days of the date of termination, not revoke, and abide by a release (which shall be substantially in the form attached hereto as Appendix A) of all claims, cooperate with the Company in the event of litigation and fully comply with Executive’s obligations under Sections 6 and 7 below.
provided, however, that the Executive has provided written notice (which shall set forth in reasonable detail the specific conduct of the Company that constitutes Good Reason and the specific provisions of this Agreement on which Executive relies) to the Company of the existence of any condition described in any one of the subparagraphs (a), (b), or (c) within thirty (30) days of the initial existence of such condition, and the Company has not cured the condition within thirty (30) days of the receipt of such notice. Any termination of employment by the Executive for Good Reason pursuant to Section 5.3 must occur no later than the date that is the three (3) month anniversary of the initial existence of the condition giving rise to the termination right.
6
Company is terminated by reason of Executive’s death or Total Disability (as defined below), subject to the requirements of applicable law:
“Total Disability” shall mean any physical or mental disability that has prevented Executive from (a)(i) performing one or more of the essential functions of Executive’s position for a period of not less than ninety (90) days in any twelve (12) month period and (ii) which is expected to be of permanent or indeterminate duration but expected to last at least twelve (12) continuous months or result in death of the Executive as determined (y) by a physician selected
7
by the Company or its insurer or (z) pursuant to the Company’s benefit programs; or (b) reporting to work for ninety (90) or more consecutive business days and being unable to engage in any substantial activity.
8
Executive acknowledges that during the course of Executive’s employment with the Company and its subsidiaries, Executive will be exposed to documents and other information regarding the confidential affairs of the Company, its subsidiaries, affiliates and strategic partners, including without limitation, information about their past, present and future financial condition, pricing strategy, prices, suppliers, cost information, business and marketing plans, the markets for their products, key personnel, past, present or future actual or threatened litigation, trade secrets and other intellectual property, current and prospective customer lists, operational methods, acquisition plans, prospects, plans for future development and other business affairs and information about the Company and its subsidiaries, affiliates and strategic partners not readily available to the public (the “Confidential Information”). Executive further acknowledges that the services to be performed under this Agreement are of a special, unique, unusual, extraordinary and intellectual character. In recognition of the foregoing, the Executive covenants and agrees as follows:
9
activity for a Competitor of the Company or any of its subsidiaries, whether as a principal, agent, partner, officer, director, employee, independent contractor, investor, consultant or stockholder (except as a less than five percent (5%) shareholder of a publicly traded company) or otherwise. A “Competitor” shall mean any individual or entity that engages in the same or substantially similar business as one or more business units of the Company or its subsidiaries. As of the Effective Date, it is understood that the Company’s business units include: (1) pharmacy benefits management (“PBM”), including the administration of pharmacy benefits for businesses, government agencies or health plans; mail order pharmacy; specialty pharmacy and Medicare Part D services; (2) the sale of prescription drugs either at retail or over the internet; and (3) retail health care (“RediClinic”). It is understood and agreed that PBM competitors include, but are not limited to, CVS Health, Express Scripts and Catamaran Corp., as well as health plans or insurers that provide PBM services. It is also understood and agreed that retail pharmacy competitors include any individual or entity that sells or has imminent plans to sell prescription drugs, including but not limited to, drugstore companies such as Walgreens Boots Alliance and CVS Health; mass merchants such as Wal-Mart Stores, Inc. and Target Corp.; and food/drug combinations such as Kroger Co., Albertsons LLC and Ahold USA. It is understood and agreed that RediClinic competitors include, but are not limited to, Walgreen’s Take Care Clinics, CVS Health’s Minute Clinics and The Little Clinic. During Executive’s employment by the Company or one of its subsidiaries and during the Restricted Period, Executive will not directly, or indirectly knowingly cause any other person to, engage in any activity that involves providing audit review or other consulting or advisory services with respect to any relationship between the Company and any third party. The “Restricted Area” means those states within the United States in which the Company, including its subsidiaries, conducts its business, including the District of Columbia and Puerto Rico. Notwithstanding anything contained herein to the contrary, Executive shall not be prohibited during the Restricted Period from engaging in the practice of law.
10
through any employee, agent or representative, any field and corporate management employee of the Company or any subsidiary or any such person who was employed by the Company or any subsidiary within 180 days of such hiring.
If Executive breaches, or threatens to commit a breach of, any of the provisions of Sections 6 or 7 above (the “Restrictive Covenants”), the Company and its subsidiaries, affiliates, strategic partners, successors or assigns shall have the following rights and remedies, each of which shall be independent of the others and severally enforceable, and each of which shall be in addition to, and not in lieu of, any other rights or remedies available to the Company or its subsidiaries, affiliates, strategic partners, successors or assigns at law or in equity.
11
render such provision enforceable), and, in its modified or reduced form, such provision shall then be enforceable.
Executive agrees to indemnify and save harmless the Company from any loss, claim, damage, cost or expense of any kind (including without limitation, reasonable attorney fees) to which the Company may be subjected by virtue of a breach by Executive of the foregoing representations, warranties, and covenants.
12
Except as necessary for the Company and its subsidiaries, affiliates, strategic partners, successors or assigns or Executive to specifically enforce or enjoin a breach of this Agreement (to the extent such remedies are otherwise available), the parties agree that any and all disputes that may arise in connection with, arising out of or relating to this Agreement, or any dispute that relates in any way, in whole or in part, to Executive’s employment with the Company or any subsidiary, the termination of that employment or any other dispute by and between the parties or their subsidiaries, affiliates, strategic partners, successors or assigns, shall be submitted to final and binding arbitration in the Commonwealth of Pennsylvania according to the National Employment Dispute Resolution Rules and procedures of the American Arbitration Association at the time in effect. The Company shall be responsible for any filing, administrative or arbitrator fees that exceed the amount it would cost to file a claim in a court of competent jurisdiction in the Commonwealth of Pennsylvania. This arbitration obligation extends to any and all claims that may arise by and between the parties or their subsidiaries, affiliates, strategic partners, successors or assigns, and expressly extends to, without limitation, claims or causes of action for wrongful termination, impairment of ability to compete in the open labor market, breach of an express or implied contract, breach of the covenant of good faith and fair dealing, breach of fiduciary duty, fraud, misrepresentation, defamation, slander, infliction of emotional distress, disability, loss of future earnings, and claims under the Pennsylvania Constitution, the United States Constitution, and applicable state and federal fair employment laws, federal and state equal employment opportunity laws, and federal and state labor statutes and regulations, including, but not limited to, the Civil Rights Act of 1964, as amended, the Fair Labor Standards Act, as amended, the Americans With Disabilities Act of 1990, as amended, the Rehabilitation Act of 1973, as amended, the Employee Retirement Income Security Act of 1974, as amended, the Age Discrimination in Employment Act of 1967, as amended, and any other state or federal law. Executive understands that by entering into this Agreement, Executive is waiving Executive’s rights to have a court determine Executive’s rights, including under federal, state or local statutes prohibiting employment discrimination, including sexual harassment and discrimination on the basis of age, race, color, religion, national origin, disability, veteran status or any other factor prohibited by governing law. Executive further understands that there is no intent herein to interfere with the Equal Employment Opportunity Commission’s right to enforce the laws it oversees or your right to file an administrative charge of employment discrimination or a similar state or local administrative agency.
Neither this Agreement, nor any of Executive’s rights or obligations hereunder, may be assigned or otherwise subject to hypothecation by Executive. The Company may assign its rights and obligations hereunder, and Executive hereby consents to any such assignment, in whole or in part, (i) to any of the Company’s subsidiaries, affiliates, or parent corporations; or (ii) to any other successor or assign in connection with the sale of all or substantially all of the Company’s assets or stock or in connection with any merger, acquisition and/or reorganization involving the Company.
13
All notices and other communications under this Agreement shall be in writing and shall be: (i) in writing; (ii) delivered personally, by fax, by electronic mail, by courier service, or by certified or registered mail, first class postage prepaid and return receipt requested; (iv) deemed to have been received on the date of delivery or, if sent by certified or registered mail, on the third (3rd) business day after the mailing thereof, or if sent by fax, twenty-four (24) hours after transmission of a fax; and (iv) addressed as follows (or to such other address as the Party entitled to notice shall hereafter designate in accordance with the terms hereof):
|
If to the Company: |
Rite Aid Corporation 30 Hunter Lane Camp Hill, Pennsylvania 17011 Attention: EVP, Chief Human Resources Officer Fax: (717) 760-7867 Email: jkazmaier@riteaid.com |
|
If to Executive: |
Paul D. Gilbert, at Executive’s last address shown on the payroll records of the Company. |
Any party may change such party’s address for notices by notice duly given pursuant hereto.
14
15
On the first payroll date after the expiration of the Deferral Period, all payments that would have been made during the Deferral Period (whether in a single lump sum or in installments) shall be paid as a single lump sum to Executive or, if applicable, Executive’s beneficiary. This section shall not apply to any payment which meets the short term deferral exception to 409A or constitutes “separation pay” as described in Treasury Regulation Section 409A-1(b)(9) (in general, payments (i) that are made on an involuntary separation from service which (ii) do not exceed the lesser of two (2) times (x) the Executive’s annualized compensation for the taxable year preceding the year in which the separation from service occurs or (y) the Code Section 401(a)(17) limit on compensation for the year in which separation from service occurs and (iii) are paid in total by the end of the second calendar year following the calendar year in which the separation from service occurs).
For purposes of 409A, each payment and each installment described in this Agreement shall be considered a separate payment from each other payment or installment and to the extent required by 409A, a payment due upon termination of employment will only be paid upon Executive’s separation from service within the meaning of such term under 409A.
16
Exhibit 10.46
IN WITNESS WHEREOF, Executive and the Company have executed this Agreement as of the date first written above.
RITE AID CORPORATION
/s/ Jessica Kazmaier
By: Jessica Kazmaier
Its: EVP, Chief Human Resources Officer
EXECUTIVE
/s/ Paul D. Gilbert
Paul D. Gilbert
APPENDIX A TO EMPLOYMENT AGREEMENT
GENERAL RELEASE OF CLAIMS
This General Release of Claims (this “Release”) is made and entered into by [NAME] (“Employee”) pursuant to Section 5.3 of the Employment Agreement between Employee and Rite Aid Corporation (the “Company”), dated as of [●] (the “Employment Agreement”).
A-2
A-3
* * *
IN WITNESS WHEREOF, Employee has signed this Release as of the date indicated below.
|
[NAME] |
|
|
|
______________________________________
Date: _________________________________ |
Exhibit 22
List of Guarantor Subsidiaries
The Guaranteed Notes are jointly and severally guaranteed on a full and unconditional basis by Rite Aid Corporation (incorporated in Delaware) and the following 100% owned subsidiaries of Rite Aid Corporation as of August 29, 2020:
|
|
|
|---|---|
|
Entity |
Jurisdiction of Incorporation or Organization |
|
|
|
|
Harco, Inc. |
Alabama |
|
K & B Alabama Corporation |
Alabama |
|
Rite Aid Lease Management Company (a California corporation) |
California |
|
Thrifty Corporation (a California corporation) |
California |
|
Thrifty PayLess, Inc. (a California corporation) |
California |
|
Rite Aid of Connecticut, Inc. |
Connecticut |
|
1515 West State Street Boise, Idaho, LLC (a Delaware limited liability company) |
Delaware |
|
Ascend Health Technology, LLC (a Delaware limited liability company) |
Delaware |
|
Design Rx Holdings, LLC (a Delaware limited liability company) |
Delaware |
|
Eckerd Corporation (a Delaware corporation) |
Delaware |
|
Envision Pharmaceutical Holdings LLC (a Delaware limited liability company) |
Delaware |
|
EnvisionRx Puerto Rico, Inc. (a Delaware corporation) |
Delaware |
|
Genovese Drug Stores, Inc. (a Delaware corporation) |
Delaware |
|
Health Dialog Services Corporation (a Delaware corporation) |
Delaware |
|
Hunter Lane, LLC (a Delaware limited liability company) |
Delaware |
|
JCG (PJC) USA, LLC (a Delaware limited liability company) |
Delaware |
|
JCG Holdings (USA), Inc. (a Delaware corporation) |
Delaware |
|
K & B, Incorporated (a Delaware corporation) |
Delaware |
|
Maxi Drug North, Inc. (a Delaware corporation) |
Delaware |
|
Maxi Drug South, L.P. (a Delaware limited partnership) |
Delaware |
|
Maxi Drug, Inc. (a Delaware corporation) |
Delaware |
|
Munson & Andrews, LLC (a Delaware limited liability company) |
Delaware |
|
Name Rite, LLC (a Delaware limited liability company) |
Delaware |
|
P.J.C. Distribution, Inc. (a Delaware corporation) |
Delaware |
|
P.J.C. Realty Co., Inc. (a Delaware corporation) |
Delaware |
|
PJC Lease Holdings, Inc. (a Delaware corporation) |
Delaware |
|
PJC Manchester Realty LLC (a Delaware limited liability company) |
Delaware |
|
PJC Revere Realty LLC (a Delaware limited liability company) |
Delaware |
|
PJC Special Realty Holdings, Inc. (a Delaware corporation) |
Delaware |
|
RediClinic Associates, Inc. (a Delaware corporation) |
Delaware |
|
RediClinic LLC (a Delaware limited liability company) |
Delaware |
|
|
|
|---|---|
|
Entity |
Jurisdiction of Incorporation or Organization |
|
|
|
|
RediClinic of PA, LLC (a Delaware limited liability company) |
Delaware |
|
Rite Aid Corporation (PARENT) |
Delaware |
|
Rite Aid Drug Palace, Inc. (a Delaware corporation) |
Delaware |
|
Rite Aid Hdqtrs. Corp. (a Delaware corporation) |
Delaware |
|
Rite Aid Hdqtrs. Funding, Inc. (a Delaware corporation) |
Delaware |
|
Rite Aid of Delaware, Inc. (a Delaware corporation) |
Delaware |
|
Rite Aid Online Store Inc. (a Delaware corporation) |
Delaware |
|
Rite Aid Payroll Management Inc. (a Delaware corporation) |
Delaware |
|
Rite Aid Realty Corp. (a Delaware corporation) |
Delaware |
|
Rite Aid Specialty Pharmacy LLC (a Delaware limited liability company) |
Delaware |
|
Rite Aid Transport, Inc. (a Delaware corporation) |
Delaware |
|
Rite Investments Corp. (a Delaware corporation) |
Delaware |
|
Rite Investments Corp., LLC (a Delaware limited liability company) |
Delaware |
|
Rx Choice, Inc. (a Delaware corporation) |
Delaware |
|
The Jean Coutu Group (PJC) USA, Inc. (a Delaware corporation) |
Delaware |
|
Thrift Drug Inc. (a Delaware corporation) |
Delaware |
|
Advance Benefits, LLC |
Florida |
|
Envision Medical Solutions, LLC |
Florida |
|
First Florida Insurers of Tampa, LLC |
Florida |
|
Rite Aid of Georgia, Inc. |
Georgia |
|
Rite Aid of Indiana, Inc. |
Indiana |
|
Rite Aid of Kentucky, Inc. |
Kentucky |
|
K & B Louisiana Corporation |
Louisiana |
|
K & B Services, Incorporated |
Louisiana |
|
Rite Aid of Maine, Inc. |
Maine |
|
GDF, Inc. |
Maryland |
|
READ'S, Inc. |
Maryland |
|
Rite Aid of Maryland, Inc. |
Maryland |
|
PJC of Massachusetts, Inc. (a Massachusetts corporation) |
Massachusetts |
|
PJC Realty MA, Inc. (a Massachusetts corporation) |
Massachusetts |
|
1740 Associates, LLC |
Michigan |
|
Apex Drug Stores, Inc. |
Michigan |
|
PDS-1 Michigan, Inc. |
Michigan |
|
Perry Distributors, Inc. |
Michigan |
|
Perry Drug Stores, Inc. |
Michigan |
|
RDS Detroit, Inc. |
Michigan |
|
Rite Aid of Michigan, Inc. |
Michigan |
|
Laker Software, LLC |
Minnesota |
|
K & B Mississippi Corporation |
Mississippi |
|
MedTrak Services, L.L.C. |
Missouri |
|
Envision Pharmaceutical Services, LLC |
Nevada |
|
Rite Aid of New Hampshire, Inc. |
New Hampshire |
|
Lakehurst and Broadway Corporation |
New Jersey |
|
|
|
|---|---|
|
Entity |
Jurisdiction of Incorporation or Organization |
|
|
|
|
Rite Aid of New Jersey, Inc. |
New Jersey |
|
Rite Aid of New York, Inc. (a New York corporation) |
New York |
|
Rite Aid Rome Distribution Center, Inc. (a New York corporation) |
New York |
|
EDC Drug Stores, Inc. |
North Carolina |
|
Rite Aid of North Carolina, Inc. |
North Carolina |
|
4042 Warrensville Center Road - Warrensville Ohio, Inc. |
Ohio |
|
5600 Superior Properties, Inc. |
Ohio |
|
Broadview and Wallings-Broadview Heights Ohio, Inc. |
Ohio |
|
Envision Pharmaceutical Services, LLC |
Ohio |
|
Gettysburg and Hoover - Dayton, Ohio, LLC |
Ohio |
|
Orchard Pharmaceutical Services, LLC |
Ohio |
|
Rite Aid of Ohio, Inc. |
Ohio |
|
RX Options, LLC |
Ohio |
|
The Lane Drug Company |
Ohio |
|
Rite Aid of Pennsylvania, LLC (Formerly Rite Aid of Pennsylvania, Inc.) |
Pennsylvania |
|
PJC of Rhode Island, Inc. |
Rhode Island |
|
Rite Aid of South Carolina, Inc. |
South Carolina |
|
K & B Tennessee Corporation |
Tennessee |
|
Rite Aid of Tennessee, Inc. |
Tennessee |
|
K & B Texas Corporation (a Texas corporation) |
Texas |
|
RCMH, LLC (a Texas limited liability company) |
Texas |
|
Rx Initiatives, L.L.C. |
Utah |
|
Maxi Green, Inc. |
Vermont |
|
PJC of Vermont, Inc. |
Vermont |
|
Rite Aid of Vermont, Inc. |
Vermont |
|
Rite Aid of Virginia, Inc. |
Virginia |
|
Rite Aid of Washington, D.C., Inc. |
Wash. D.C. |
|
5277 Associates, Inc. |
Washington |
|
Rite Aid of West Virginia, Inc. |
West Virginia |
|
Design Rx, LLC |
Wyoming |
|
Design Rxclusives, LLC |
Wyoming |
Exhibit 31.1
Certification of Chief Executive Officer
I, Heyward Donigan, President and Chief Executive Officer, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Rite Aid Corporation (the “Registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors:
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
|
|
|
|
|
Date: October 6, 2020 |
|
|
|
|
|
|
|
|
By: |
/s/ HEYWARD DONIGAN |
|
|
|
Heyward Donigan |
|
|
|
President and Chief Executive Officer |
Exhibit 31.2
Certification of Chief Financial Officer
I, Matthew C. Schroeder, Executive Vice President and Chief Financial Officer, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Rite Aid Corporation (the “Registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
d. Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and
5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors:
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.
|
|
|
|
|
Date: October 6, 2020 |
|
|
|
|
|
|
|
|
By: |
/s/ MATTHEW C. SCHROEDER |
|
|
|
Matthew C. Schroeder |
|
|
|
Executive Vice President and Chief Financial Officer |
|
|
|
|
Exhibit 32
Certification of CEO and CFO Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Rite Aid Corporation (the “Company”) for the quarterly period ended August 29, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Heyward Donigan, as President and Chief Executive Officer of the Company, and Matthew C. Schroeder, as Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
/s/ HEYWARD DONIGAN |
|
|
|
Name: |
Heyward Donigan |
|
|
Title: |
President and Chief Executive Officer |
|
|
Date: |
October 6, 2020 |
|
|
|
|
|
|
|
|
|
|
/s/ MATTHEW C. SCHROEDER |
|
|
|
Name: |
Matthew C. Schroeder |
|
|
Title: |
Executive Vice President and Chief Financial Officer |
|
|
Date: |
October 6, 2020 |
|